<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004504.pub4" GROUP_ID="BACK" ID="021302021122385942" MERGED_FROM="" MODIFIED="2014-12-18 21:02:18 +0000" MODIFIED_BY="Claire Munhall" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.27">
<COVER_SHEET MODIFIED="2014-12-18 15:41:12 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-08-27 21:14:59 -0400" MODIFIED_BY="[Empty name]">Herbal medicine for low-back pain</TITLE>
<CONTACT>
<PERSON ID="12685" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joel</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Gagnier</LAST_NAME>
<SUFFIX>ND MSc PhD(c.)</SUFFIX>
<POSITION/>
<EMAIL_1>jgagnier@umich.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology, School of Public Health</DEPARTMENT>
<ORGANISATION>University of Michigan</ORGANISATION>
<ADDRESS_1>1415 Washington Heights</ADDRESS_1>
<ADDRESS_2>Rm M5158</ADDRESS_2>
<CITY>Ann Arbor</CITY>
<ZIP>48109-2029</ZIP>
<REGION>MI</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 (519) 567-9690</PHONE_1>
<PHONE_2>+1 (734) 936-2084</PHONE_2>
<FAX_1>+1 (519) 974-9690</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-12-18 13:30:52 -0500" MODIFIED_BY="Claire Munhall">
<PERSON ID="18970378471870912987120615150838" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Hanna</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Oltean</LAST_NAME>
<SUFFIX>MPH</SUFFIX>
<POSITION>Clinical Research Coordinator</POSITION>
<EMAIL_1>holtean@umich.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Orthopaedic Surgery</DEPARTMENT>
<ORGANISATION>University of Michigan</ORGANISATION>
<ADDRESS_1>24 Frank Lloyd Wright Dr</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ann Arbor</CITY>
<ZIP>48106</ZIP>
<REGION>MI</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 734 930-7462</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1312111530148236038937140963785" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Chris</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Robbins</LAST_NAME>
<SUFFIX>MPA, PhDC</SUFFIX>
<POSITION>Senior Research Specialist</POSITION>
<EMAIL_1>crobbins@umich.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Orthopaedic Surgery</DEPARTMENT>
<ORGANISATION>University of Michigan</ORGANISATION>
<ADDRESS_1>24 Frank Lloyd Wright Dr.</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ann Arbor</CITY>
<ZIP>48106-0391</ZIP>
<REGION>MI</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 734 930-7462</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5654" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Maurits</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>van Tulder</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION/>
<EMAIL_1>maurits.van.tulder@vu.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Health Sciences, Faculty of Earth and Life Sciences</DEPARTMENT>
<ORGANISATION>VU University</ORGANISATION>
<ADDRESS_1>PO Box 7057</ADDRESS_1>
<ADDRESS_2>Room U454</ADDRESS_2>
<CITY>Amsterdam</CITY>
<ZIP>1007 MB</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 20 598 6587</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6788" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Brian</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Berman</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Professor and Director, Complementary Medicine Program</POSITION>
<EMAIL_1>bberman@som.umaryland.edu</EMAIL_1>
<EMAIL_2/>
<URL>http://www.compmed.umm.edu</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Center for Integrative Medicine</DEPARTMENT>
<ORGANISATION>University of Maryland School of Medicine</ORGANISATION>
<ADDRESS_1>520 W. Lombard St</ADDRESS_1>
<ADDRESS_2>2nd Floor</ADDRESS_2>
<CITY>Baltimore</CITY>
<ZIP>21201</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 410 706 6182</PHONE_1>
<PHONE_2/>
<FAX_1>+1 410 706 6210</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5205" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Claire</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bombardier</LAST_NAME>
<SUFFIX>MD, FRCPC</SUFFIX>
<POSITION>Senior Scientist</POSITION>
<EMAIL_1>claire.bombardier@utoronto.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute for Work &amp; Health</ORGANISATION>
<ADDRESS_1>481 University Avenue, Suite 800</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5G 2E9</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 927 2027 ext: 2133</PHONE_1>
<PHONE_2/>
<FAX_1>+1 416 927 4167</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12685" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joel</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Gagnier</LAST_NAME>
<SUFFIX>ND MSc PhD(c.)</SUFFIX>
<POSITION/>
<EMAIL_1>jgagnier@umich.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology, School of Public Health</DEPARTMENT>
<ORGANISATION>University of Michigan</ORGANISATION>
<ADDRESS_1>1415 Washington Heights</ADDRESS_1>
<ADDRESS_2>Rm M5158</ADDRESS_2>
<CITY>Ann Arbor</CITY>
<ZIP>48109-2029</ZIP>
<REGION>MI</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 (519) 567-9690</PHONE_1>
<PHONE_2>+1 (734) 936-2084</PHONE_2>
<FAX_1>+1 (519) 974-9690</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-12-18 08:53:49 -0500" MODIFIED_BY="Shireen Harbin">
<UP_TO_DATE>
<DATE DAY="31" MONTH="8" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="9" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-12-18 15:41:12 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-12-18 15:40:46 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>The review authors conducted a new search, added four new studies to the review, and used up-to-date methods. The new studies examined the effects of topical capsaicin, acupressure with lavender oil, comfrey root extract, and Brazilian arnica on chronic soft tissue and lower back pain.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-12-18 15:41:12 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>The review authors conducted a new search, added four new trials to the review, and used up-to-date methods. The newly included trials examined the effects of topical capsaicin, acupressure with lavender oil, comfrey root extract, and Brazilian arnica on chronic soft tissue and lower back pain.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-11-29 11:44:17 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-11-29 11:44:14 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to a new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-11-29 11:44:17 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Natural Health Products Directorate/Canadian Institutes of Health Research</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>National Center for Complementary and Alternative Medicine</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-12-18 13:44:37 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-09-02 16:50:27 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-08-07 13:52:52 -0400" MODIFIED_BY="[Empty name]">Herbal medicine for low-back pain</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-02 16:50:27 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>We examined the evidence regarding the effect of herbal medicine on pain in people with non-specific low-back pain (LBP).</P>
<P>
<B>Background<BR/>
</B>Back pain is common and up to 35% of the population can be affected in a given month. Non-specific LBP is defined as pain between the lowest rib and the bottom of the buttocks that is not caused by serious, underlying problems such as rheumatoid arthritis, infection, fracture, cancer, or sciatica due to a ruptured disc or other pressure on nerves. Herbal medicines taken orally or applied to the skin are being used to treat many conditions including back pain.</P>
<P>
<B>Study characteristics<BR/>
</B>Researchers from the Cochrane Collaboration examined the evidence available up to August 5, 2013. Fourteen studies tested six herbal medications and included 2050 adults with non-specific acute or chronic LBP. Two oral herbal medications, <I>Harpagophytum procumbens</I> (devil's claw) and <I>Salix alba</I> (white willow bark), were compared to placebo (fake or sham pills) or to rofecoxib (Vioxx®). Three topical creams, plasters, or gels, <I>Capsicum frutescens</I> (cayenne), <I>Symphytum officinale</I> L. (comfrey), and <I>Solidago chilensis</I> (Brazilian arnica), were compared to placebo creams or plasters and a homeopathic gel. One essential oil, lavender, was compared to no treatment. The average age of people included in the trials was 52 years and studies usually lasted three weeks.</P>
<P>
<B>Key results<BR/>
</B>Devil's claw, in a standardized daily dose of 50 mg or 100 mg harpagoside, may reduce pain more than placebo; a standardized daily dose of 60 mg reduced pain about the same as a daily dose of 12.5 mg of Vioxx®. While willow bark, in a standardized daily dose of 120 mg and 240 mg of salicin reduced pain more than placebo; a standardized daily dose of 240 mg reduced pain about the same as a daily dose of 12.5 mg of Vioxx® (a non-steroidal, anti-inflammatory drug). Cayenne was tested in several forms: in plaster form, it reduced pain more than placebo and about the same as the homeopathic gel Spiroflor SLR. Two other ointment-based medications, <I>S. officinale</I> and <I>S. chilensis</I> appeared to reduce perception of pain more than placebo creams. Lavender essential oil applied by acupressure appeared effective in reducing pain and improving flexibility compared to conventional treatment. Adverse effects were reported, but appeared to be primarily confined to mild, transient gastrointestinal complaints or skin irritations.</P>
<P>
<B>Quality of the evidence<BR/>
</B>Most included trials were at low risk of bias and the quality of the evidence was mainly very low to moderate. A moderate grade of evidence was only found for <I>C. frutescens</I>. Trials only tested the effects of short term use (up to six weeks). Authors of eight of the included trials had a potential conflict of interest and four other authors did not disclose conflicts of interest. Vioxx® has been withdrawn from the market because of adverse effects, so all three substances should be compared to readily-available pain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, for relative effectiveness and safety.</P>
<P>
<B>Conclusion<BR/>
</B>Low to moderate quality evidence shows that four herbal medicines may reduce pain in acute and chronic LBP in the short-term and have few side effects. There is no evidence yet that any of these substances are safe or efficacious for long-term use. Large, well-designed trials are needed to further test the efficacy of these interventions. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-12-18 11:59:02 -0500" MODIFIED_BY="Shireen Harbin">
<ABS_BACKGROUND MODIFIED="2014-08-27 20:26:05 -0400" MODIFIED_BY="[Empty name]">
<P>Low-back pain (LBP) is a common condition and imposes a substantial economic burden upon people living in industrialized societies. A large proportion of people with chronic LBP use complementary and alternative medicine (CAM), visit CAM practitioners, or both. Several herbal medicines have been purported for use in treating people with LBP. This is an update of a Cochrane Review first published in 2006.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-08-27 20:26:12 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of herbal medicine for non-specific LBP.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-12-18 11:59:02 -0500" MODIFIED_BY="Shireen Harbin">
<P>We searched the following electronic databases up to September 2014: MEDLINE, EMBASE, CENTRAL, CINAHL, Clinical Trials.gov, World Health Organization International Clinical Trials Registry Portal and PubMed; checked reference lists in review articles, guidelines and retrieved trials; and personally contacted individuals with expertise in this area. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-08-27 20:27:03 -0400" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials (RCTs) examining adults (over 18 years of age) suffering from acute, sub-acute, or chronic non-specific LBP. The interventions were herbal medicines which we defined as plants used for medicinal purposes in any form. Primary outcome measures were pain and function.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-04 10:27:04 -0400" MODIFIED_BY="[Empty name]">
<P>A library scientist with the Cochrane Back Review Group conducted the database searches. One review author contacted content experts and acquired relevant citations. We downloaded full references and abstracts of the identified studies and retrieved a hard copy of each study for final inclusion decisions. Two review authors assessed risk of bias, GRADE criteria (<A HREF="GRADE 2004">GRADE 2004</A>), and CONSORT compliance and a random subset were compared to assessments by a third individual. Two review authors assessed clinical relevance and resolved any disagreements by consensus.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-02 16:44:53 -0400" MODIFIED_BY="[Empty name]">
<P>We included 14 RCTs (2050 participants) in this review. One trial on <I>Solidago chilensis M.</I> (Brazilian arnica) (20 participants) found very low quality evidence of reduction in perception of pain and improved flexibility with application of Brazilian arnica-containing gel twice daily as compared to placebo gel. <I>Capsicum frutescens</I> cream or plaster probably produces more favourable results than placebo in people with chronic LBP (three trials, 755 participants, <I>moderate quality evidence</I>). Based on current evidence, it is not clear whether topical capsicum cream is more beneficial for treating people with acute LBP compared to placebo (one trial, 40 participants, <I>low quality evidence</I>). Another trial found equivalence of <I>C. frutescens</I> cream to a homeopathic ointment (one trial, 161 participants, <I>very low quality evidence</I>). Daily doses of <I>Harpagophytum procumbens</I> (devil's claw), standardized to 50 mg or 100 mg harpagoside, may be better than placebo for short-term improvements in pain and may reduce use of rescue medication (two trials, 315 participants, <I>low quality evidence</I>). Another <I>H. procumbens </I>trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (Vioxx®) but was of very low quality (one trial, 88 participants, <I>very low quality</I>). Daily doses of <I>Salix alba</I> (white willow bark), standardized to 120 mg or 240 mg salicin, are probably better than placebo for short-term improvements in pain and rescue medication (two trials, 261 participants, <I>moderate quality evidence</I>). An additional trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (one trial, 228 participants) but was graded as very low quality evidence. <I>S. alba</I> minimally affected platelet thrombosis versus a cardioprotective dose of acetylsalicylate (one trial, 51 participants). One trial (120 participants) examining <I>Symphytum officinale L.</I> (comfrey root extract) found low quality evidence that a Kytta-Salbe comfrey extract ointment is better than placebo ointment for short-term improvements in pain as assessed by VAS. Aromatic lavender essential oil applied by acupressure may reduce subjective pain intensity and improve lateral spine flexion and walking time compared to untreated participants (one trial, 61 participants,<I> very low quality evidence</I>). No significant adverse events were noted within the included trials.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-12-09 10:47:40 -0500" MODIFIED_BY="[Empty name]">
<P>
<I>C. frutescens</I> (Cayenne) reduces pain more than placebo. Although <I>H. procumbens</I>, <I>S. alba</I>, <I>S. officinale L.</I>, <I>S. chilensis</I>, and lavender essential oil also seem to reduce pain more than placebo, evidence for these substances was of moderate quality at best. Additional well-designed large trials are needed to test these herbal medicines against standard treatments. In general, the completeness of reporting in these trials was poor. Trialists should refer to the CONSORT statement extension for reporting trials of herbal medicine interventions.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-12-18 13:44:37 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-12-18 08:53:00 -0500" MODIFIED_BY="Shireen Harbin">
<P>Low-back pain (LBP) and its related disability are major public health problems across industrialized nations. As a result, research efforts have intensified to identify effective treatment and management strategies for people with LBP (<LINK REF="REF-Mounce-2002" TYPE="REFERENCE">Mounce 2002</LINK>). Point prevalence estimates of LBP vary widely depending on the methodology used, but range from 12% to 40% of the population (<LINK REF="REF-Friedley-2010" TYPE="REFERENCE">Friedley 2010</LINK>). Additionally, several studies indicate that LBP prevalence is increasing over time (<LINK REF="REF-Friedley-2010" TYPE="REFERENCE">Friedley 2010</LINK>). Data from a United States. national survey from 2002 reported a three-month prevalence of 26.4%, with higher prevalence among American Indians and Alaskan Natives (35.0%), and lower prevalence among Asian Americans (19.0%) (<LINK REF="REF-Deyo-2006" TYPE="REFERENCE">Deyo 2006</LINK>). LBP prevalence peaks between the ages of 45 to 64 years and is more common among lower socioeconomic status groups, as defined by income and education (<LINK REF="REF-Deyo-2006" TYPE="REFERENCE">Deyo 2006</LINK>). Lifetime prevalence of LBP is estimated at 67% (<LINK REF="REF-Deyo-2006" TYPE="REFERENCE">Deyo 2006</LINK>).</P>
<P>In the United States, back pain accounts for 19 million physician visits, 250 million workdays lost, and $14 billion (USD) in direct expenditures (<LINK REF="REF-Grabois-2005" TYPE="REFERENCE">Grabois 2005</LINK>). Indirect costs, excluding short- and long-term disability, are estimated at up to $100 billion (USD) per year (<LINK REF="REF-Eisenberg-2012" TYPE="REFERENCE">Eisenberg 2012</LINK>). LBP-related disorders caused 2.63 million annual emergency department (ED) visits, or 2.3% of all visits to EDs in the United States (<LINK REF="REF-Friedman-2010" TYPE="REFERENCE">Friedman 2010</LINK>). This amounts to substantial societal productivity losses and an economic burden for health-care systems in many industrialized countries (<LINK REF="REF-Mounce-2002" TYPE="REFERENCE">Mounce 2002</LINK>).</P>
<P>Wide variations in the medical and surgical management of LBP reflect widespread professional uncertainty about optimal care of people with LBP (<LINK REF="REF-Eisenberg-2012" TYPE="REFERENCE">Eisenberg 2012</LINK>). Over 1000 randomized controlled trials (RCTs) have been published evaluating all types of conservative, complementary, or surgical treatments for LBP that are commonly used in primary and secondary care (<LINK REF="REF-Koes-2006" TYPE="REFERENCE">Koes 2006</LINK>). A special focus issue of <I>The Spine Journal </I>reviewed 25 categories of treatment presented for the management of chronic LBP (<LINK REF="REF-Haldeman-2008" TYPE="REFERENCE">Haldeman 2008</LINK>). Several interventions are included in clinical practice guidelines on LBP, including: back schools, non-steroidal anti-inflammatory drugs (NSAIDs), the McKenzie method, needle acupuncture, spinal manipulation, trigger point injections, and watchful waiting (<LINK REF="REF-Haldeman-2008" TYPE="REFERENCE">Haldeman 2008</LINK>). A summary of European clinical guidelines for chronic LBP includes cognitive behavior therapy, supervised exercise therapy, educational interventions, biopsychosocial treatment, and short-term use of NSAIDs and weak opioids (<LINK REF="REF-Koes-2006" TYPE="REFERENCE">Koes 2006</LINK>).</P>
<P>Although systematic reviews suggest that few of these interventions have sufficient evidence to suggest benefit, it does appear that acute LBP can usually be effectively managed by encouraging activity, reassurance, and short-term symptom control (analgesics or NSAIDs) (<LINK REF="REF-Koes-2006" TYPE="REFERENCE">Koes 2006</LINK>). Treatments that demonstrate some effectiveness for the management of chronic LBP include exercise therapy, behavioural treatment, and multidisciplinary treatment programs, as well as short-term use of analgesics or NSAIDs (<LINK REF="REF-Koes-2006" TYPE="REFERENCE">Koes 2006</LINK>).</P>
<P>Research in complementary and alternative medicine (CAM) has increased over the past 15 years. Rigorous literature is growing steadily and is subsequently clarifying the validity of these techniques (e.g., <LINK REF="REF-Vickers-2000" TYPE="REFERENCE">Vickers 2000</LINK>) . Specifically, the number of randomized trials of complementary treatments has doubled approximately every five years (<LINK REF="REF-Vickers-2000" TYPE="REFERENCE">Vickers 2000</LINK>) and currently, the Cochrane Complementary Medicine Field Trials Registry contains over 43,000 records. In addition, CAM teaching institutions are now beginning to teach principles of evidence-based medicine and clinical epidemiology (<LINK REF="REF-Mills-2002" TYPE="REFERENCE">Mills 2002</LINK>; <LINK REF="REF-Sierpina-2002" TYPE="REFERENCE">Sierpina 2002</LINK>). These initiatives are well placed, given the large number of visits to CAM practitioners (<LINK REF="REF-Metcalfe-2010" TYPE="REFERENCE">Metcalfe 2010</LINK>; <LINK REF="REF-Frass-2012" TYPE="REFERENCE">Frass 2012</LINK>). A recent population survey in Canada found that 12.4% of Canadians visited a CAM practitioner in the year they were surveyed, between 2001-2005 (<LINK REF="REF-Metcalfe-2010" TYPE="REFERENCE">Metcalfe 2010</LINK>). A review article on the international acceptance and use of CAM found prevalence rates between 5.0% to 74.8%, with an overall average prevalence of 32.2% (<LINK REF="REF-Frass-2012" TYPE="REFERENCE">Frass 2012</LINK>). Follow-up studies indicate that there has been a steady increase in CAM use (<LINK REF="REF-Frass-2012" TYPE="REFERENCE">Frass 2012</LINK>). More CAM users are women, middle-aged, educated, and experiencing chronic disease (<LINK REF="REF-Metcalfe-2010" TYPE="REFERENCE">Metcalfe 2010</LINK>; <LINK REF="REF-Frass-2012" TYPE="REFERENCE">Frass 2012</LINK>). Back pain or back problems are one of the five most common medical conditions for which CAM has most often been used (<LINK REF="REF-Frass-2012" TYPE="REFERENCE">Frass 2012</LINK>). Among people reporting back problems, between 16.8% to 57.2% seek CAM treatments (<LINK REF="REF-Frass-2012" TYPE="REFERENCE">Frass 2012</LINK>).</P>
<P>Several herbal medicines are reported treatments for various types of pain. These include <I>Cammiphora molmol </I>(myrrh) , <I>Capsicum frutescens (</I>capsicum), <I>Salix alba </I>(white willow bark), <I>Melaleuca alternifolia </I>(tea tree) , <I>Angelica sinensis </I>(don quai) , <I>Aloe vera </I>(aloe), <I>Thymus officinalis </I>(Thyme), <I>Menthe peperita </I>(peppermint), <I>Arnica montana </I>(Arnica), <I>Curcuma longa </I>(curcumin), <I>Tanacetum parthenium </I>(feverfew), <I>Harpagophytum procumbens (devil's claw) </I>, and <I>Zingiber officinale (ginger) </I>(<LINK REF="REF-Blumenthal-1998" TYPE="REFERENCE">Blumenthal 1998</LINK>). Many have been the subject of extensive biochemical research, resulting in the delineation of their pharmacological and physiological effects (<LINK REF="REF-Mills-2000" TYPE="REFERENCE">Mills 2000</LINK>). For example, the mechanism of <I>C. frutescens </I>is partially related to its ability to deplete substance P, a neurotransmitter for pain perception (<LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>). <I>S. alba</I> is a platelet inhibitor and analgesic, and <I>H. procumbens </I>has analgesic and anti-inflammatory properties (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>). In addition, some of these herbal species have been clinically tested for the relief of symptoms of LBP (<LINK REF="REF-Krivoy-2000" TYPE="REFERENCE">Krivoy 2000</LINK>; <LINK REF="STD-Laudahn-2001a" TYPE="STUDY">Laudahn 2001a</LINK>; <LINK REF="REF-Mills-2000" TYPE="REFERENCE">Mills 2000</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>).</P>
<P>Given the large public health and economic burden LBP causes and the large number of people with LBP who regularly visit CAM practitioners, a systematic review of these herbal medicines was warranted.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-08-27 20:33:35 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of herbal medicine compared to placebo, no intervention, or other interventions in the treatment of non-specific LBP.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-12-18 12:12:26 -0500" MODIFIED_BY="Shireen Harbin">
<SELECTION_CRITERIA MODIFIED="2014-12-18 08:53:00 -0500" MODIFIED_BY="Shireen Harbin">
<CRIT_STUDIES MODIFIED="2014-08-27 20:34:50 -0400" MODIFIED_BY="[Empty name]">
<P>RCTs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-08-27 20:34:50 -0400" MODIFIED_BY="[Empty name]">
<P>Adults aged over 18 years, suffering from acute (lasting up to six weeks), sub-acute (six to 12 weeks) or chronic (longer than 12 weeks) non-specific LBP.</P>
<P>We defined LBP as pain localized to the area between the costal margin or the 12th rib to the inferior gluteal fold. Non-specific LBP indicated that no specific cause was detectable, such as infection, neoplasm, metastasis, osteoporosis, rheumatoid arthritis, fracture, inflammatory process, or radicular syndrome (<LINK REF="REF-Waddell-1996" TYPE="REFERENCE">Waddell 1996</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-08-27 20:34:58 -0400" MODIFIED_BY="[Empty name]">
<P>For the purpose of this Cochrane Review, we defined a herbal medicine as all or part of a plant used for medicinal purposes, administered orally (ingestion) or applied topically. This definition did not include plant substances smoked (e.g. <I>Cannabis sativa</I>), individual chemicals derived from plants, or synthetic chemicals that were based on constituents of plants. However, we considered <I>C. sativa </I>and other plants that can be smoked as herbal medicines in this Cochrane Review if they were ingested. Various forms of oral herbal medicine include: standardized extracts (encapsulated or tablet form), tinctures (alcohol, glycerine, etc.), dried herb (encapsulated or tablet form), raw whole herb infusion (e.g. tea) and decoction (e.g. boiled-down tea). Topical herbal applications include ointments, essential oils, creams (petroleum or glycerine-based), powders, plasters, and poultices. We excluded opioids as they bridge the definitions of herbal medicine and analgesic.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-12-18 08:53:00 -0500" MODIFIED_BY="Shireen Harbin">
<OL>
<LI>Pain intensity (e.g. visual analogue scale (VAS), numerical rating scale (NRS)) and proportion of pain-free patients (use of analgesic medications);</LI>
<LI>Back pain specific functional status measured by validated instruments (e.g. Roland Disability Questionnaire (RDQ), Owestry Disability index (ODI), modified Aberdeen LBP Scale);</LI>
<LI>Overall improvement (% reporting subjective improvement, NRS);</LI>
<LI>Return to Work or Work Status (% of population, number of days of absenteeism);</LI>
<LI>Lumbar flexibility (measured by Schober method, fingertip-to-ground distance).</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-12-18 12:12:26 -0500" MODIFIED_BY="Shireen Harbin">
<P>We used the search strategy recommended by the Cochrane Back Review Group (CBRG) (<LINK REF="REF-Bombardier-2011" TYPE="REFERENCE">Bombardier 2011</LINK>; <LINK REF="REF-Furlan-2009" TYPE="REFERENCE">Furlan 2009</LINK>). The search stratgies for the identification of RCTs recommended by <LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK> was also used in some of the strategies in this update.</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-12-18 12:12:26 -0500" MODIFIED_BY="Shireen Harbin">
<P>We searched the following electronic databases up to September 11, 2014:<BR/>
</P>
<OL>
<LI>MEDLINE (OvidSP, 1946 to September Week 1 2014) and MEDLINE In-Process &amp; Other Non-Indexed Citations (OvidSP, September 10, 2014)</LI>
<LI>EMBASE (Ovid SP, 1980 to 2014 Week 36)</LI>
<LI>Cochrane Central Registry of Controlled Trials (CENTRAL, The Cochrane Library<I>; </I>Issue 8 of 12, August 2014)</LI>
<LI>Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCO, 1981 to 2014)</LI>
<LI>
<A HREF="http://clinicaltrials.gov/ct2/search/advanced">ClinicalTrials.gov</A>
</LI>
<LI>World Health Organization International Clinical Trials Registry Portal (<A HREF="http://apps.who.int/trialsearch/AdvSearch.aspx">WHO ICTRP</A>)</LI>
<LI>PubMed</LI>
</OL>
<P>Searches have been conducted annually since 2009. CENTRAL (which contains the Complementary Medicine Field trials register) and CINAHL were added to the strategy in 2009, the trials registries ClinicalTrials.gov and WHO ICTRP were added in 2012, and Medline In-Process &amp; Other non-Indexed Citaitons was added in 2013. A supplemental search of PubMed was added in 2014 to capture items not indexed in Medline using the strategy recommended by <LINK REF="REF-Duffy-2014" TYPE="REFERENCE">Duffy 2014</LINK>. The 2014 search strategies for all databases are included in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> contains the 2009 strategies and highlights updates to these strategies to 2013.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-12-18 12:07:27 -0500" MODIFIED_BY="Shireen Harbin">
<P>We reviewed reference lists in review articles, guidelines, and in the retrieved trials. Also we contacted individuals with expertise in herbal medicine and LBP to identify additional trials. We translated non-English articles and JJG and MvT discussed these articles following the same procedures described below.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-02 17:09:02 -0400" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-08-27 20:36:04 -0400" MODIFIED_BY="[Empty name]">
<P>A library scientist with the CBRG conducted the electronic searches. Two review authors (HNO and JJG) independently selected studies based on title, abstract, and keywords. We included studies that met the inclusion criteria. If it was unclear from the title and abstract if a study fulfilled the inclusion criteria, we retrieved the full-text article for final selection. We used a consensus method to resolve any disagreements.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-08-27 20:36:33 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors (HNO and JJG) independently extracted the data from each trial using a standardized form. We extracted the following data from each trial: recruitment, characteristics of the trial population (age, gender), setting (e.g. year, country of origin), duration of LBP (acute, subacute, or chronic), previous treatment for LBP, number of participants initially recruited, number of participants randomized, number of drop-outs or withdrawals, duration of intervention, type of herbal medicine used (plant name and form of delivery and dosage), standardization information (e.g. percentage of active constituent per delivery unit), characteristics of the control intervention (type and duration), types of outcome measures, summary statistics, timing of outcome assessments, compliance, adverse effects due to intervention, and authors' conclusions as to the intervention's effectiveness.</P>
<SUBSECTION>
<HEADING LEVEL="3">Reporting quality</HEADING>
<P>One review author (HNO) assessed the reporting quality of each included trial using the CONSORT statement (<LINK REF="REF-Moher-2012" TYPE="REFERENCE">Moher 2012</LINK>) and the CONSORT statement for herbal interventions (<LINK REF="REF-Gagnier-2006c" TYPE="REFERENCE">Gagnier 2006c</LINK>). HNO scored each criterion as 'yes' (Y), 'no' (N) or 'don't know' (DK). 'Yes' indicated that the criterion was met. 'No' reflected the lack of fulfilment of that criterion. 'Don't know' reflected the fact that there was insufficient information to determine if this criterion was fulfilled or not. We considered a trial to have high reporting quality if it contained at least 50% of the CONSORT checklist items or at least 50% of the CONSORT for herbal interventions items.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-09-02 17:08:03 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors (HNO and JJG) independently assessed methodological quality using the method recommended by <LINK REF="REF-Furlan-2009" TYPE="REFERENCE">Furlan 2009</LINK>. Given JJG's familiarity with the literature, trials were not blinded for authors, institution or journal. We used the 12 items in the methodological quality assessment reflecting internal validity, together with operational definitions, recommended by the CBRG in their updated method guidelines for systematic reviews to assess methodological quality (<LINK REF="REF-Furlan-2009" TYPE="REFERENCE">Furlan 2009</LINK>). We scored each criterion as high, low, or unclear. 'High' indicated that the criterion was not met. 'Low' reflected the fulfilment of that criterion. 'Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not. We considered a trial to have low risk of bias if the trial met over 50% (6/12) of internal validity items and we found no other serious flaws.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-09-02 17:09:02 -0400" MODIFIED_BY="[Empty name]">
<P>We planned to analyse dichotomous outcomes by calculating the relative risk values (RR). For continuous outcomes, we planned to calculate the mean difference (MD) when the same instrument was used to measure outcomes or the standardized mean difference (SMD) when different instruments were used to measure the outcomes. We planned to use 95% confidence intervals (95% CI) to express the uncertainty of the findings. However, we were unable to combine the trials through meta-analysis because of insufficient data and clinical heterogeneity. Therefore we conducted a qualitative analysis of trial findings.</P>
<P>Two review authors (HNO and JJG) independently assessed the overall quality of the evidence for each outcome using the GRADE approach (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>), as recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and adapted in the updated CBRG method guidelines (<LINK REF="REF-Furlan-2009" TYPE="REFERENCE">Furlan 2009</LINK>). Domains that decreased the quality of the evidence include: study design and risk of bias, inconsistency of results, indirectness, imprecision (sparse data) and other factors (e.g. reporting bias).</P>
<P>We determined the overall quality of evidence for each outcome by combining the assessments on all domains. The five levels of evidence include:</P>
<UL>
<LI>
<B>High quality evidence: </B>there are consistent findings among at least 75% of RCTs with low risk of bias, consistent, direct and precise data and no known or suspected publication biases. Further research is unlikely to change either the estimate or our confidence in the results.</LI>
<LI>
<B>Moderate quality evidence: </B>one of the domains is not met. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</LI>
<LI>
<B>Low quality evidence: </B>two of the domains are not met. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</LI>
<LI>
<B>Very low quality evidence: </B>three of the domains are not met. We are very uncertain about the results.</LI>
<LI>
<B>No evidence: </B>no RCTs were identified that addressed this outcome</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Clinical relevance</HEADING>
<P>One review author (JJG) assessed the clinical relevance of each trial using these five questions:</P>
<OL>
<LI>Are the patients described in detail so that you can decide whether they are comparable to those that you see in your practice?</LI>
<LI>Are the interventions and treatment settings described well enough so that you can provide the same for your patients?</LI>
<LI>Were all clinically relevant outcomes measured and reported?</LI>
<LI>Is the size of the effect clinically important?</LI>
<LI>Are the likely treatment benefits worth the potential harms?</LI>
</OL>
</SUBSECTION>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-12-18 13:44:37 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-12-18 13:44:37 -0500" MODIFIED_BY="[Empty name]">
<P>We identified 775 references in total and excluded 725 references after reviewing titles and abstracts. Fifty papers were retrieved in full, 34 of which were excluded. We have listed the reasons for exclusion in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> section. We excluded a further six articles, for a total of 40 excluded articles, because they were notes or comments on a previous study or repeated articles. Threfore, in the original search we included 10 articles(<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>). In this search update (July 2005 to August 5, 2013), we identified a total of four citations that met the inclusion criteria (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>; <LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>), which we included with the 10 articles (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>) identified in earlier literature searches. In a search update, through September 2014, we identified 5 citations with none meeting the inclusion criteria. </P>
<P>Three trials used an oral form of the herbal species <I>H. procumbens</I> (devil's claw; <LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>), three trials used oral <I>S. alba</I> (white willow bark; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>), five trials used topical <I>C. frutescens</I> (cayenne; <LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>), one used lavender essential oil applied by acupressure (<LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>), one used topical <I>S. chilensis </I>(Brazilian arnica; <LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK>), and one used topical <I>Symphytum officinale L.</I> (comfrey; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>).</P>
<P>Four trials compared various oral herbal medicines with placebo (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>). Two trials compared oral herbal medicines to standard pain medications (<LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>). Six trials compared topical herbal medicines to placebo (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>). One trial compared a topical herbal medicine to a topical homeopathic medicine (<LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>) and one trial compared a topical herbal medicine to no treatment (<LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>).</P>
<P>The three <I>H. procumbens</I> trials included participants with acute exacerbations of chronic non-specific LBP (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>). Similarly, the three trials of <I>S. alba</I> preparations included homogeneous populations with acute episodes of chronic non-specific LBP (<LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>). One trial using a topical <I>C. frutescens</I> ointment included patients with acute mechanical LBP (<LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>). Two trials using a Capsicum pain plaster included participants with chronic non-specific LBP (<LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>). One trial using Capsicum cream included patients with chronic pain of the soft tissues of the musculoskeletal apparatus, with a subgroup of back pain patients (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>). A second trial using a topical Capsicum ointment included a sample of patients with either newly occurring acute LBP or acute episodes of chronic LBP (<LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>). The lavender essential oil trial included patients with non-specific sub-acute LBP (<LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>). The trial assessing <I>S. chilensis</I> included patients seeking treatment for a diagnosis of lumbago (<LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK>). Finally, the <I>S. officinale</I> trial included patients with acute non-specific upper or lower back pain (<LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>).</P>
<P>Three trials (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>) used a relatively unknown LBP scale, the Arhus Index, which was designed to monitor outcomes of clinical trials of LBP. The Arhus Index is a back-pain specific index that includes physical impairment, pain, and disability scores, which are summed into a total score (<LINK REF="REF-Manniche-1994" TYPE="REFERENCE">Manniche 1994</LINK>). The pain scale is rated by the patient and includes back pain and leg pain, with a score that ranges from 0 to 60. The disability scale consists of a questionnaire that asks about 15 daily tasks, with a score that ranges from 0 to 30. The physical impairment score is obtained by scoring on a deep knee bend, a modified Schober's test, a low-back strength test and a measure of analgesic use, with a total combined score ranging from 0 to 40. The higher the scores, the more physical impairment, pain and disability. This test takes approximately 15 minutes to complete. It has been shown to be a valid and reliable measure of LBP (<LINK REF="REF-Manniche-1994" TYPE="REFERENCE">Manniche 1994</LINK>).</P>
<P>In the <I>H. procumbens </I>trials, <LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK> used a standardized dosage of 50 mg harpagoside per day or 2400 mg of the crude extract; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK> used daily dosages of the proprietary extract WS 1531 at 600 and 1200 mg of the crude herb, which was the equivalent of 50 and 100 mg harpagoside; and <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK> used a proprietary extract of Doloteffin, containing a daily dose of 60 mg harpagoside, or 12.5 mg rofecoxib (Vioxx®).</P>
<P>In the white willow bark extract trials, <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK> utilized an extract containing 0.153 mg salicin per mg and made comparisons between daily dose of 120 mg salicin, 240 mg of salicin and a matched placebo; <LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK> used <I>S. alba</I> containing a daily dose of 240 mg salicin and compared it to 12.5 mg rofecoxib; and <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK> used a daily dose of <I>S. alba</I> containing 240 mg salicin compared to placebo and 100 mg acetylsalicyliate.</P>
<P>The five trials of topical <I>C. frutescens</I> preparations used: a topical plaster application containing 11 mg of capsaicinoids per plaster (<LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>); a plaster containing an ethonolic extract of cayenne pepper standardized to 22 µg/cm<SUP>2</SUP> of capsaicinoids (<LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>); a gel called Cremor Capsici Compositus FNA (CCC), which contains 100 mg of Capsicum Oleoresin (BPC), 10 g of glycol salicylate, 1 g of methylnictinate, and a combined 1 g of histamine hydrochloride, sorbitol, methylprahydroxybenzoate, triethanolamine, lanette wax, stearic acid, and purified water (<LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>); a gel called Rado-Sailil, containing 17.64 mg acetylsalicylate, 26.47 mg methylsalicylate, 8.82 mg glycosalicylate, 8.82 mg salicylic acid, 4.41 mg camphor, 55.14 mg menthol and 15.44 mg Capsicum Oleoresin per gram (<LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>); and a cream called Finalgon CPD Warmecreme, containing 2.2 to 2.6 g soft extract of capsici fructus acer corresponding to 53 mg capsaicin (0.05%) (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>).</P>
<P>In the trial using <I>Symphytom officinale</I>, <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK> used an ointment called Kytta-Salbe containing 35 g 99% reduced <I>Rad symphyti</I> fluid extract per 100 g.</P>
<P>The <I>S. chilensis</I> trial used a gel containing plant extract diluted in propylene glycol and added at a proportion of 5% to carbomer gel, corresponding to active substances in 5 g of dry raw material (<LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK>).</P>
<P>The trial that applied lavender oil using acupressure used 3% <I>Lavandula angustifolia </I>essential oil in grape seed oil.</P>
<P>Twelve of the 14 included studies reported information regarding adverse events associated with the study medication. We have reported details of the included trials in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>We assessed the included trials for any potential conflicts of interest by looking at funding sources (public vs. private) and whether a trial author was employed by a private pharmaceutical, nutraceutical, or herbal medicine manufacturer. Three trials reported no conflict of interest (<LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>). However, we deemed a conflict of interest possible in <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>, as several trial authors were employed by pharmaceutical companies. The authors of eight trials had potential conflicts of interest (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>; <LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>). In five trials, an author was employed by a pharmaceutical company (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>), one trial was funded by a professional academy (<LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>), one trial was funded by a pharmaceutical company (<LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>), and for one trial, the experimental herbal medicine was supplied by a company (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>). The remaining trial was funded by an oil company; we could not determine whether this was a conflict of interest (<LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK>). In the final three trials (<LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>; <LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>), we considered conflicts of interest unlikely.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-02 18:18:58 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors (HNO and JG) assessed the methodological quality criteria in full of all included papers. Agreement between the review authors was over 98%. The mean score for methodological quality assessment criteria (<LINK REF="REF-Furlan-2009" TYPE="REFERENCE">Furlan 2009</LINK>) of all included studies was 7.2, with a median score of 7.5 and a range of four to ten. Using a cut-off point of six fulfilled criteria out of 12, 11 trials (79%) were at low risk of bias (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>; <LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>). The main methodological shortcomings of the <I>H. procumbens</I> trials included a lack of reporting of allocation concealment, compliance rates, controls for co-interventions and acceptability of withdrawal or drop-out rates during the follow-up period. Of the included <I>S. alba</I> trials, one was an open-label trial and the additional two did not report allocation concealment, compliance rates, controls for co-interventions, or the acceptability of withdrawal or drop-out rates during the follow-up period. <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>'s capsicum trial was at low risk of bias. The additional capsicum trials (<LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>) failed to report the type of randomization, allocation concealment, similarity of baselines, outcome assessor, investigator and participant blinding, comparability of co-interventions, and acceptability of compliance. The lavender <LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK> and Brazilian arnica <LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK> trials were at high risk of bias, meeting less than half of the criteria. The comfrey trial failed to report randomization and treatment allocation, blinding of the outcome assessor, and similarity of the groups at baseline. The risk of bias assessment of each included trial is given in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">GRADE</HEADING>
<P>We applied the GRADE criteria to the included trials as recommended in <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>. Four treatments (Capsicum cream, Capsicum plaster, <I>S. alba</I>, and devil's claw) had several RCTs investigating their use, and we subsequently assessed them on all GRADE criteria. We assessed the remaining six treatments as having moderate to very low quality of evidence, as there was only one included RCT for each treatment.</P>
<P>We downgraded the evidence from three trials to low quality evidence due to limitations in study design (<LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>, ). For two of these treatments (lavender and Brazilian arnica) there was evidence from only one RCT, therefore we downgraded the evidence to very low quality due to insufficient data and having less than 400 included participants. <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK> had no other downgrades aside from being a singular study and having less than 400 included participants, resulting in a grade of low quality<B>.</B> The trials comparing Capsicum cream or plaster to placebo for chronic LBP (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>) were analyzed together and determined to provide moderate quality evidence for this treatment. <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK> compared capsicum to placebo in acute LBP and was downgraded for study limitations and a small sample size. <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK> was the only article examining Capsicum cream compared to a homeopathic gel; therefore we graded this evidence as very low quality due to a small sample size and low patient compliance. We downgraded the evidence from the trials comparing <I>H. procumbens</I> to placebo (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>) for imprecise data and a sample size of less than 400, resulting in an overall grade of low quality. <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK> compared <I>H. procumbens</I> to rofecoxib was the only article to examine this comparison, and thus we downgraded the evidence due to study limitations (problems with allocation concealment and compliance) and a small sample size. Two trials assessed <I>S. alba</I> compared to placebo (<LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>); we rated this evidence as moderate quality due to a small sample size, potential selection bias, and differences in baseline characteristics. Finally, we rated the evidence from the single trial comparing <I>S. alba</I> to rofecoxib (<LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>) as very low quality due to indirectness, imprecision and a small sample size.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical relevance</HEADING>
<P>Four trials met all five clinical relevance criteria (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>). Of the trials testing <I>H. procumbens</I>, two trials did not meet items four and five (<LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>). Of the <I>S. alba</I> trials, one did not meet item one (<LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>), one did not meet items four and five (<LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>) and it was not possible to tell if one trial fulfilled items four and five or not (<LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>). Of the <I>C. frutescens</I> trials, three did not meet item one (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>), one did not meet item three (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>), two did not meet items four and five (<LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>), and for <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>, it was not possible to tell if items four and five were met or not. <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK> did not meet items 1 to 3, while <LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK> did not meet item three and it was not possible to tell if it met item 5.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reporting (CONSORT)</HEADING>
<P>We assessed reporting in the published articles using the CONSORT statement and the CONSORT statement for herbal interventions. On average, the included trials had information on 45.3% of the CONSORT items, with a range from 19.4% (<LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>) to 59.5% (<LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>). Items missing in over half of the included trials included a description of trial design, any changes to methods or outcomes after trial commencement, how sample size was determined, explanation of interim analyses and stopping guidelines, type of randomization, method used to implement the random allocation sequence (including who generated it), methods for subgroup or adjusted analyses, dates defining periods of recruitment and follow-up, why the trial was stopped, trial limitations and sources of bias, generalizability, registration number and name of trial registry, where the full protocol can be accessed, and sources of funding and support. Using the arbitrary cut-off of 50% of items, the average reporting in these trials was poor. However, eight trials had good completeness of reporting (<LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>; <LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>; <LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>; <LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>).</P>
<P>Also, we assessed reporting using the CONSORT statement for herbal interventions. Using these guidelines, the average trial included information on 45.4% of the checklist items, with a range from 27.3% (<LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>) to 58.2% (<LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>). Information that was reported in under half of the trials included the Latin binomial for the herbal medicine product, the part of the plant used, the authority and family name of all herbal ingredients, the name of the manufacturer of the product, the type and concentration of extraction solvent used, the drug to extract ratio, the method of authentication of raw material, whether a voucher specimen was retained and where it is stored, how the duration of drug administration was determined, weight amount of all known herbal product constituents, qualitative testing of product, a description of the practitioners, concomitant herbal medicine use, and discussion of results in relation to other available products. Using the arbitrary cut-off of 50% of items, the average reporting in these studies was poor. However, five trials had good completeness of reporting (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>; <LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-12-18 13:36:03 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1a) H. procumbens (devil's claw) verses placebo</HEADING>
<P>The included two trials testing <I>H. procumbens</I> enrolled participants suffering from acute exacerbations of chronic LBP lasting longer than six months (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Chronic LBP</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">50 mg Harpagoside dose</HEADING>
<P>Two four-week trials, which included 315 participants, tested extracts of <I>H. procumbens</I> standardized to 50 mg harpagoside (H) per day versus placebo (<LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>; <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>). Both trials found a significant increase in the number of pain-free patients in the 50 mg H group (9% to 17%) versus placebo (2% to 5%). One trial found that for participants taking 50 mg H, the percentage with no pain or mild LBP increased over the four week period (from 2% in week 1, to 24% in week 4), whereas the percentage with unbearable or severe pain decreased over the four weeks (from 59% in week 1 to 35% in week 4, (<LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>). Tramadol consumption decreased more in both trials in the group that received 50 mg H than in the group that received placebo. However, this decrease did not reach statistical significance in <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK> and <LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK> did not perform a statistical test on this measure. Both trials used the Arhus Index. The overall Arhus score improved by 21% in both the 50 mg H group and the placebo group, with no significant difference between groups. The pain subscale was significantly improved in favour of the 50 mg H group in both trials (median change for those with current LBP of 43%, <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>; median change of 34%, <LINK REF="STD-Chrubasik-1996" TYPE="STUDY">Chrubasik 1996</LINK>), which was a greater improvement than that of the group that received an additional 100 mg H in one trial (median change for those with current LBP of 37%, <LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>).</P>
<P>Based on this low quality evidence, a daily dose of 50 mg harpagoside in an aqueous extract of <I>H. procumbens</I> may reduce pain more than placebo in the short-term, in patients with acute episodes of chronic non-specific LBP. Long-term treatment data are not yet available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">100 mg Harpagoside dose</HEADING>
<P>
<LINK REF="STD-Chrubasik-1999" TYPE="STUDY">Chrubasik 1999</LINK>, a four-week trial which included 197 participants, tested <I>H. procumbens </I>standardized to 100 mg harpagoside (H) per day versus placebo. The number of patients who were pain-free for at least five days in the fourth week of treatment was significantly higher (N = 10) than in either the placebo (N = 3) or lower dose (50 mg H) groups (N = 6). Half of the pain-free patients in the 100 mg H group had a neurological deficit at the start of the trial. The changes from baseline in the overall Arhus Index, the pain index, invalid index and physical impairment index did not differ between the three groups. The percentage of patients with no or mild LBP increased over the four-week period, whereas the percentage with unbearable or severe pain decreased.</P>
<P>Therefore, there is low quality evidence that a daily dose of 100 mg harpagoside in an aqueous extract of <I>H. procumbens</I> may lead to a greater number of patients who are pain-free for at least five days, in the fourth week of treatment of acute episodes of chronic non-specific LBP. Superiority of the higher dose has not been shown.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1b) S. alba versus placebo</HEADING>
<P>We included two trials which enrolled participants suffering from acute exacerbations of chronic LBP lasting longer than six months (<LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Chronic LBP</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">120 mg salicin dose</HEADING>
<P>A four-week trial, including 210 participants, tested two doses of <I>S. alba</I>, standardized to either 120 mg or 240 mg salicin (S) per day, against placebo (N = 70 for each group; <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>). The number of patients who were pain-free for at least five days in the fourth week of treatment increased from baseline in the placebo (N = 4), 120 mg salicin group (N = 15) and the 240 mg salicin group (N = 27), with the trend for dose being significant. The number of patients requiring relief medication (Tramadol) during each week decreased to 33 during week four for the placebo group, 10 for the 120 mg salicin group and three for the 240 mg salicin group; with the trend for dose being significant. The total Arhus Index, pain index, invalid index, and physical impairment index did not change from baseline for the placebo group but improved in the groups receiving either 120 mg or 240 mg salicin. The trend for dose was significant, with the group receiving 240 mg salicin showing more improvement in the total Arhus Index score and the pain index than the group receiving 120 mg salicin group.</P>
<P>There is moderate quality evidence that a daily dose of 120 mg salicin from an extract of <I>S. alba</I> results in more pain-free patients in the short-term for individuals with acute episodes of chronic non-specific LBP.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">240 mg salicin dose</HEADING>
<P>Two trials included 261 patients tested 240 mg salicin (<LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK>; <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>). Results for the <LINK REF="STD-Chrubasik-2000" TYPE="STUDY">Chrubasik 2000</LINK> trial are reported above. In summary, for the 240 mg salicin per day, there were more participants who were pain-free for five days during the fourth week of treatment, and fewer patients required relief medication. There was a trend of greater improvements with higher dose for all outcomes and significant differences between the groups receiving 120 mg and 240 mg salicin for the total Arhus Index score and the pain index. The additional trial by <LINK REF="STD-Krivoy-2001" TYPE="STUDY">Krivoy 2001</LINK>, which was designed to test platelet aggregation of <I>S. alba</I> extract, did not measure clinically relevant outcomes. Although the trial authors stated that fewer patients in the group receiving 240 mg salicin required rescue medication (i.e. Tramadol) than in the placebo group, they did not provide any data.</P>
<P>Based on moderate quality evidence a daily dose of 240 mg salicin from an extract of <I>S. alba</I> probably reduces pain more than either placebo or a daily dose of 120 mg of salicin in the short term for individuals with acute episodes of chronic non-specific LBP.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1c) C. frutescens versus placebo</HEADING>
<P>We included four trials: one that enrolled participants with acute LBP (<LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK>), though the actual duration of LBP was not described; two trials with participants with chronic LBP that had lasted longer than three months (<LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK>; <LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK>); and one trial which included participants with chronic soft tissue pain (with a subset of patients experiencing chronic back pain) and did not describe duration of pain (<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Acute LBP</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Cream</HEADING>
<P>
<LINK REF="STD-Ginsberg-1987" TYPE="STUDY">Ginsberg 1987</LINK> gave 40 participants with acute mechanical LBP either a cream called Rado-Salil, containing salicylate and capsicum (N = 20) or a placebo cream containing bergamot and lavender (N = 20) for 14 days. At day three, there was an improvement in pain score in the Rado-Salil group of almost 2 cm on the VAS, which was significantly better than the placebo group. By day 14, the improvement increased to 3.79 cm, which was also significantly greater than the placebo group. In addition, both patients and physicians rated the effect of Rado-Salil more favourably than the placebo group rated the effect of their cream.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chronic LBP</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Cream</HEADING>
<P>
<LINK REF="STD-Chrubasik-2010" TYPE="STUDY">Chrubasik 2010</LINK> included 281 participants suffering from chronic non-specific soft-tissue pain who were randomly allocated to either a placebo cream group (N = 141) or a Capsicum cream group (N = 140) for 21 days. A reduction in pain by at least 30% was achieved in 75.0% of the Capsicum group and 40.9% of the placebo group. A reduction in pain by at least 50% was achieved in 50.0% of the Capsicum group and 28.8% of the placebo group. The median relative pain sum score improvement was 48.9% in the Capsicum group and 22.5% in the placebo group. The capsicum treatment was rated as either "excellent" or "good" by patients in 59.3% of cases compared to 21.9% for the placebo group. The absolute number of days where patients reported an analgesic effect were &gt; 70% among the Capsicum group and below 30% in the placebo group. For the majority of patients, the maximum effect was reached within two hours after application, and in 50% of patients the effect persisted for two to four hours.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Plaster</HEADING>
<P>
<LINK REF="STD-Keitel-2001" TYPE="STUDY">Keitel 2001</LINK> included 154 participants with acute episodes of chronic non-specific LBP, who were randomly allocated to either a placebo plaster group (N = 77) or a Capsicum plaster group (n = 77) for three weeks. A reduction in pain by at least 30% was achieved in 60.9% of the Capsicum group and 42.1% of the placebo group. A reduction in pain by at least 50% was reported in 35.1% of the Capsicum group and 17.1% of the placebo group. The total Arhus score improved significantly more in the group using Capsicum (38.5%) than in the group using placebo (28%). Physician global ratings of efficacy were considered "excellent" or "good" in 75.7% of those using Capsicum and 47.4% of those using the placebo. After treatment, 13.5% of participants using Capsicum and 6.6% using placebo were symptom-free. Compliance was 90.6% in the group using Capsicum and 88.1% in the group using placebo.</P>
<P>
<LINK REF="STD-Frerick-2003" TYPE="STUDY">Frerick 2003</LINK> enrolled 320 participants suffering from chronic non-specific LBP, who were randomly allocated to either a placebo plaster group (N = 180) or a Capsicum plaster group (N = 180) for 21 days. The total Arhus Index score decreased significantly more in the group using Capsicum (33%) than in the group using placebo (22%). The Arhus compound pain score decreased significantly more in the group using Capsicum (42%) than in those using placebo (31%). A reduction in pain by at least 30% was achieved in 67% of those using Capsicum and 49% in those using placebo, and a reduction in pain by at least 50% was seen in 45% and 24%, respectively. The Arhus subscale for physical impairment also decreased significantly more in the Capsicum group (21%) than in the placebo group (10%). Similar results were found for the disability subscale (35% vs. 22%, respectively). The capsicum treatment was rated as either "excellent" or "good" by investigators in 74% of cases compared to 36% for the placebo group. Compliance was reported as being "very good" or "good" in both groups (91% and 93%, respectively).</P>
<P>Therefore, there is moderate quality of evidence that a plaster and moderate quality evidence that a cream of <I>C. frutescens</I> reduces pain and improves function more than placebo in the short-term for individuals with chronic non-specific LBP. There is very low GRADE of evidence that a cream of <I>C. frutescens</I> may reduce pain more than placebo in the short-term for individuals with acute non-specific LBP.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1d) S. officinale versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Acute LBP</HEADING>
<P>
<LINK REF="STD-Giannetti-2010" TYPE="STUDY">Giannetti 2010</LINK>
 included 120 participants with acute non-specific upper or lower back pain, and randomized participants to eithercomfrey ointment treatment (N = 60) or placebo ointment (N = 60) for five days, with three applications per day. Over the course of the treatment, pain intensity by VAS decreased 95.2% in the comfrey group, a significant difference from the placebo group (37.8%). Reported back pain at rest decreased 97.4% in the comfrey group compared to 39.6% in the placebo group. Pressure algometry values in the trigger point increased 125% in the comfrey group and 71.8% in the placebo group.  Global assessment of efficacy by patients and investigators were all superior in the comfrey group (good or excellent for 80%) compared to the placebo group (good or excellent for 18.4%) (<LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>).</P>
<P>There is low quality evidence that a cream of <I>S. officinale</I> reduces pain more than placebo in the short-term for individuals with acute episodes of upper or lower back pain.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1e) S. chilensis versus placebo</HEADING>
<P>
<LINK REF="STD-da-Silva-2010" TYPE="STUDY">da Silva 2010</LINK> randomized 20 patients seeking treatment for lumbago to either treatment with <I>S. chilensis</I> gel (N = 10) or placebo gel (N = 10) for 15 days. Each gel was applied twice per day. The <I>S. chilensis</I> treatment group reported a significant change in pain, as assessed by VAS at the end of the treatment period compared to baseline values. Also they experienced a significant increase in lumbar flexibility. Participants treated with placebo did not experience significant changes in perception of pain or lumbar flexibility over the course of treatment. The placebo and treatment groups were not statistically compared to one another.</P>
<P>Therefore, based on low quality evidence, <I>S. chilensis</I> gel may reduce pain and improve lumbar flexibility in the short term for people with lumbago (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2a) H. procumbens versus rofecoxib</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Chronic LBP</HEADING>
<P>
<LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK> included 88 patients with acute episodes of chronic non-specific LBP in a six-week trial, and tested <I>H. procumbens</I> standardized to 60 mg harpagoside per day (N = 44) versus 12.5 mg rofecoxib per day (N = 44). There were no significant differences in the number of patients who were pain-free for at least five days in the sixth week of treatment in the 60 mg <I>H. procumbens</I> group (10/44) than in the rofecoxib group (5/44). The number of patients with improvements in pain scores did not differ between the two groups. This trial may lack power due to its small sample size. The number of patients using rescue medication (Tramadol) decreased from baseline in both groups, but did not differ between groups at week six. At the end of six weeks, there were no differences between groups for current LBP, scores on the Arhus pain index, invalid index, functional index, or the total score for the Arhus Index. The health assessment questionnaire (HAQ) improved in both groups during the six-week period, with no differences between groups.</P>
<P>Therefore, based on current evidence, it is unclear whether a daily dose of 60 mg harpagoside in an aqueous extract of <I>H. procumbens </I>differs in effectiveness compared to a daily dose of 12.5 mg rofecoxib in the short-term for individuals with acute episodes of chronic non-specific LBP (<I>very low quality evidence</I>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2b) S. alba versus rofecoxib</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Chronic LBP</HEADING>
<P>
<LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK> included 228 participants with acute episodes of chronic non-specific LBP in a four-week trial, and tested <I>S. alba</I> standardized to provide a daily dose of 240 mg salicin against 12.5 mg per day of rofecoxib. Both the rofecoxib and the 240 mg salicin groups improved by 44% on the pain scale, the Arhus invalid index, pain index, and physical impairment index. The percentage of patients requiring NSAIDs, Tramadol, or both was 10% for the <I>S. alba</I> group and 13% for the rofecoxib group. Approximately 90% of physicians and patients rated either treatment as effective and close to 100% rated either treatment as acceptable.</P>
<P>It is unclear, based on current evidence whether a daily dose of 240 mg salicin (of an extract of <I>S. alba</I>) is more effective than a daily dose of 12.5 mg rofecoxib in the short term for people with acute episodes of chronic non-specific LBP in the short-term (<I>very low quality evidence</I>; <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3) C. frutescens versus homeopathic treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Acute and chronic LBP</HEADING>
<P>
<LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK> included 161 participants, who were a mixed group of patients with new acute LBP and acute episodes of chronic LBP. Participants were randomly allocated to either a Spiroflor SLR homeopathic gel (SLR) group (N = 83) or the CCC, the Capsici Oleoresin gel, group (N = 78) for a period of seven days. Each of the gels was applied at 3 g/day. Both groups showed a significant reduction in pain on the VAS scale, with a decrease of 38.2 mm in the SLR group and 36.6 mm in the CCC group. In the SLR group, 50% of participants reported that treatment was 80% effective and 18% reported total (100%) effectiveness. In the CCC group, this was 55% and 15%, respectively. There were also no differences in the proportion of participants using paracetamol, the proportion of participants still unable to work at the end of the study, and overall efficacy.</P>
<P>Based on current evidence, it is unclear whether Spiroflor SLR homeopathic gel and CCC gel differ in efficacy (<I>very low quality evidence</I>;<LINK REF="SOF-10" TYPE="SOF">Summary of findings table 10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4) Lavender versus conventional treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Acute LBP</HEADING>
<P>
<LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK> included 61 participants with non-specific sub-acute LBP for most days in the previous four weeks. The trial used lavender essential oil, applied by acupressure eight times over a three-week period, to treat 32 participants. "Conventional treatment", which is not described in the text, was used to treat the remaining 29 participants. One week after the end of the study, the intervention group reported significantly lower pain ratings (39% reduction) than the control group (no change). Both groups reported similar decreases in pain duration. Improvements were also seen in the lavender group in walking time and fingertip-to-floor distance, but these changes were functionally insignificant (9% and 4% changes, respectively). Acceptance of the intervention was rated as "satisfied" or "strongly satisfied" by 93% in the lavender-treatment group. Trial authors did not report acceptance of the control group.</P>
<P>Therefore, based on current evidence it is unclear whether lavender essential oil applied via acupressure treatments significantly reduces perception of pain among people reporting non-specific sub-acute LBP (<I>very low quality evidence</I>; <LINK REF="SOF-09" TYPE="SOF">Summary of findings table 9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-02 18:27:46 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Quality of the evidence</HEADING>
<P>We included 14 RCTs in this review. Three trials examined <I>H. procumbens</I> (devil's claw), three trials examined <I>S. alba </I>(white willow bark), five assessed <I>C. frutescens</I> (cayenne), one examined <I>S. officinale </I>(comfrey), one <I>Lavandula angustifolia</I> (lavender), and one <I>S. chilensis </I>(Brazilian arnica). Although reporting quality in the included trials was poor, risk of bias is not directly related to reporting quality (<LINK REF="REF-Huwiler_x002d_Muntener-2002" TYPE="REFERENCE">Huwiler-Muntener 2002</LINK>). Therefore, the risk of bias of poorly reported trials remains unclear. We attempted to contact all trial authors to clarify aspects of trials that were inadequately reported in the published manuscripts but did not receive replies from several corresponding trial authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Efficacy</HEADING>
<P>The results of the included trials suggest that specific herbal medicines may be effective for short-term (four to six weeks) improvement in pain and functional status for individuals with acute episodes of chronic non-specific LBP. Ten trials were placebo-controlled while four trials were comparative. There is insufficient evidence to make definitive conclusions regarding those trials comparing herbal medicine interventions to standard drugs. Two of the comparative trials used Vioxx® as a comparator (<LINK REF="STD-Chrubasik-2001a" TYPE="STUDY">Chrubasik 2001a</LINK>; <LINK REF="STD-Chrubasik-2003" TYPE="STUDY">Chrubasik 2003</LINK>), another used a homeopathic topical preparation (<LINK REF="STD-Stam-2001" TYPE="STUDY">Stam 2001</LINK>), and the last compared to "conventional treatment" (<LINK REF="STD-Yip-2004" TYPE="STUDY">Yip 2004</LINK>). Given the severe adverse effects of Vioxx® and its subsequent removal from the retail market, additional trials testing these herbal medicines against standard drugs (acetaminophen, NSAIDs) are needed.</P>
<P>Although the majority of these trials were considered to have homogenous LBP populations, we were unable to pool and analyse trial data due to lack of reporting of sufficient raw data. Therefore, we could not provide quantitative evidence of efficacy of the six individual herbal medicines used in these trials. Instead, we used the GRADE criteria to synthesize the data. The included trials did not assess long term efficacy (e.g. return to work, recurrence) and therefore remains to be determined.</P>
<P>Given the overwhelming evidence that conflicts of interest may bias trial results, we assessed the potential for conflict of interest in these trials. We determined that a conflict of interest was a possibility in eight included trials. It is not possible to determine the specific influence of these potential conflicts on results of this Cochrane Review.</P>
<P>This review highlights research that, when combined, indicates that there are at least four herbal medicines that have low to moderate quality of evidence for the short-term treatment of acute episodes of non-specific LBP. These interventions are reported to have very few side effects, but more research is required to extensively explore the safety of these herbals. The adverse effects appear to be primarily confined to mild, transient gastrointestinal complaints and skin irritations. Large observational studies are needed to explore the relative safety of these herbals to standard medications such as acetaminophen and NSAIDs.</P>
<P>This review has several strengths, including the comprehensive search strategy, the inclusion of only the highest quality trial design and use of suggested methods for systematic reviews of interventions for LBP (<LINK REF="REF-Furlan-2009" TYPE="REFERENCE">Furlan 2009</LINK>). One drawback of this review is that many included trials were authored by the same trialists (Chrubasik and colleagues). It is possible that the results may be systematically biased in some way. It is imperative that trials of these herbal medicines be repeated by other research groups and in different settings.</P>
<P>The qualitative analysis used here may be regarded as a strength and drawback. That is, though it would have been incorrect to statistically combine data from heterogeneous trials, the qualitative method used does not provide information on the size of the treatment effect. Without this quantitative data it is hard to determine whether these herbal interventions cause clinically significant effects on patients suffering from non-specific LBP. Quantitative analyses were precluded by incomplete reporting of data in these trials. Evidence suggests that reporting of clinical trials, irrespective of the intervention, is poor (e.g. <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). Specifically, RCTs of herbal interventions report less than half of the required information as outlined by the CONSORT statement (<LINK REF="REF-Gagnier-2006a" TYPE="REFERENCE">Gagnier 2006a</LINK>). An extension of the CONSORT statement for the reporting of RCTs of herbal medicine interventions has been developed and should be referred to when reporting such trials (<LINK REF="REF-Gagnier-2006b" TYPE="REFERENCE">Gagnier 2006b</LINK>). These guidelines will aid trialists in planning, implementing, and reporting controlled clinical trials.</P>
<P>Another point of note is from the known heterogeneity of herbal medicine products. That is, herbal medicines often vary in the type of preparation (liquid, VS dried, VS topical) and thus in the amount of chemical constituents per dose. These variations influence the pharmacokinetics and therefore the relative efficacy of these products.</P>
</SUBSECTION>
<SUMMARY_OF_RESULTS MODIFIED="2014-09-02 16:42:07 -0400" MODIFIED_BY="[Empty name]">
<P>We included 14 trials (2050 participants) in this Cochrane Review. Daily doses of <I>H. procumbens</I> (Devil's Claw) standardized to 50 mg or 100 mg harpagoside may be better than placebo for short-term improvements in pain and reduced use of rescue medication (two trials, 315 participants, <I>low quality evidence</I>). Another <I>H. procumbens </I>trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (Vioxx®) (one trial, 88 participants, very <I>low quality evidence</I>). Daily doses of <I>S. alba</I> (White Willow Bark) standardized to 120 mg or 240 mg salicin are probably better than placebo for short-term improvements in pain and rescue medication (two trials, 261 participants, <I>moderate quality evidence</I>). An additional trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (one trial, 228 participants, <I>very low quality evidence</I>). <I>S. alba</I> minimally affected platelet thrombosis versus a cardioprotective dose of acetylsalicylate (one trial, 51 patients). <I>C. frutescens</I> cream produced more favourable results than placebo and <I>C. frutescens</I> plaster produced more favourable results than placebo in people with chronic LBP (three trials, 755 participants, <I>moderate quality evidence</I>). Also, <I>C. frutescens</I> cream was preferable to placebo in people with acute LBP (one trial, 40 patients, <I>very low quality evidence</I>). Another trial found equivalence of <I>C. frutescens</I> cream to a homeopathic ointment (one trial, 161 participants, <I>very low quality evidence</I>). <I>S. officinale L.</I> (comfrey root extract) applied three times daily may be better than placebo ointment for short-term improvements in pain (one trial, 120 participants, <I>low quality evidence</I>). <I>S. chilensis M.</I> (Brazilian arnica) found very low quality evidence of reduction in perception of pain and improved flexibility with application of Brazilian arnica-containing gel twice daily as compared to placebo gel (one trial, 20 participants<I>, very low quality evidence</I>). Aromatic lavender essential oil applied by acupressure reduced subjective pain intensity and improved lateral spine flexion and walking time compared with participants who were not offered treatment (one trial, 61 participants, <I>very low quality evidence</I>). There were no significant adverse events noted within the trials included in this Cochrane Review.</P>
</SUMMARY_OF_RESULTS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-02 18:30:05 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-02 18:30:05 -0400" MODIFIED_BY="[Empty name]">
<P>A topically applied plaster or cream of <I>C. frutescens</I>, and a cream of <I>S. officinale</I> appear to reduce pain more than placebo. These herbal medicines could be considered as a treatment option for acute (<I>S. officinale</I>) and of chronic LBP (<I>C. frutescens</I>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-08-27 20:51:08 -0400" MODIFIED_BY="[Empty name]">
<P>Additional large RCTs at low risk of bias and completely reported must be done to determine if the herbal medicines discussed above are effective in the treatment of acute and chronic LBP. In particular, more trials are needed that include people with acute and subacute LBP. Also, additional trials testing these herbal medicines against standard treatments (acetaminophen, NSAIDs) will clarify their equivalence in terms of efficacy and effectiveness. The quality of reporting in these trials was generally poor and thus trialists should refer to the CONSORT and related statements in designing and reporting clinical trials of herbal medicines.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-09-02 18:49:25 -0400" MODIFIED_BY="[Empty name]">
<P>The contents of this article are solely the responsibility of the review authors and do not necessarily represent the official views of the NCCAM, or the National Institutes of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-08-27 20:51:46 -0400" MODIFIED_BY="[Empty name]">
<P>The senior review author, JJG, previously worked as a scientist with a company that produced and sold ingredients reviewed in this Cochrane Review. MVT is a Co-ordinating Editor of the CBRG and editors are required to conduct at least one Cochrane Review. A Cochrane editor who is a Cochrane Review author is excluded from editorial decisions on the Cochrane Review of which they are contributors. Therefore, this involvement does not seem to be a source of conflict of interest in the Cochrane Collaboration.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-08-27 20:51:22 -0400" MODIFIED_BY="[Empty name]">
<P>HNO wrote the body of the review, screened trials for inclusion, assessed methodological quality and evidence, and prepared the manuscript for submission to the CBRG.</P>
<P>JJG screened trials for inclusion, assessed methodological quality and grading, edited and wrote the body of the review.</P>
<P>MVT resolved author disagreements on inclusion of articles, translated articles from German to determine inclusion, and edited the final version of the review.</P>
<P>CB edited versions of the protocol and review.</P>
<P>BB edited versions of the protocol and review.</P>
<P>CR updated and edited final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-12-18 13:42:19 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-12-18 13:42:19 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-1996" MODIFIED="2014-08-24 10:00:33 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-08-24 10:00:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Zimpfer CH, Schütt U, Ziegler R</AU>
<TI>Effectiveness of Harpagophytum procumbens in the treatment of acute low back pain</TI>
<SO>Phytomedicine</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-1999" MODIFIED="2014-08-24 10:00:47 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-08-24 10:00:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H</AU>
<TI>Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind study</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>2</NO>
<PG>118-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2000" MODIFIED="2014-08-24 10:01:34 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-08-24 10:01:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Eisenberg E, Balan E, Weinberger T, Luzzati R, Conradt C</AU>
<TI>Treatment of low back pain exacerbations with willow bark extract: A randomized double-blind study</TI>
<SO>American Journal of Medicine</SO>
<YR>2000</YR>
<VL>109</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2001a" MODIFIED="2014-08-24 10:29:40 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2001a" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:02:17 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Künzel O, Model A, Conradt C, Black A</AU>
<TI>Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain</TI>
<SO>Rheumatology</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>12</NO>
<PG>1388-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2003" MODIFIED="2014-09-02 16:44:13 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-02 16:44:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Model A, Black A, Pollak S</AU>
<TI>A randomized double-blind pilot study comparing Doloteffin and Vioxx® in the treatment of low back pain</TI>
<SO>Rheumatology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>1</NO>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2010" MODIFIED="2014-08-24 10:04:03 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-24 10:04:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Weiser T, Beime B</AU>
<TI>Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain</TI>
<SO>Phytotherapy Research</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>12</NO>
<PG>1877-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-da-Silva-2010" MODIFIED="2014-08-24 10:05:05 -0400" MODIFIED_BY="[Empty name]" NAME="da Silva 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-24 10:05:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>da Silva AG, de Sousa CPG, Koehler J, Fontana J, Christo AG, Guedes-Bruni RR</AU>
<TI>Evaluation of an extract of Brazilian Arnica (Solidago chilensis Meyen, Asteraceae) in treating lumbago</TI>
<SO>Phytotherapy Research</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>2</NO>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frerick-2003" MODIFIED="2014-08-24 10:06:19 -0400" MODIFIED_BY="[Empty name]" NAME="Frerick 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-24 10:06:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frerick H, Keitel W, Kuhn U, Schmidt S, Bredehorst A, Kuhlmann M</AU>
<TI>Topical treatment of chronic low back pain with a capsicum plaster</TI>
<SO>Pain</SO>
<YR>2003</YR>
<VL>106</VL>
<NO>1-2</NO>
<PG>59-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannetti-2010" MODIFIED="2014-08-24 10:07:11 -0400" MODIFIED_BY="[Empty name]" NAME="Giannetti 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-24 10:07:11 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannetti BM, Staiger C, Bulitta M, Predel HG</AU>
<TI>Efficacy and safety of comfrey root extract ointment in the treatment of acute upper or lower back pain: results of a double-blind, randomised, placebo controlled, multicentre trial</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>2010</YR>
<VL>44</VL>
<NO>9</NO>
<PG>637-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ginsberg-1987" MODIFIED="2014-08-24 10:08:19 -0400" MODIFIED_BY="[Empty name]" NAME="Ginsberg 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-08-24 10:08:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ginsberg F, Famaey JP</AU>
<TI>A double-blind study of topical massage with Rado-Salil ointment in mechanical low back pain</TI>
<SO>Journal of International Medical Research</SO>
<YR>1987</YR>
<VL>15</VL>
<NO>3</NO>
<PG>148-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keitel-2001" MODIFIED="2014-08-24 10:09:12 -0400" MODIFIED_BY="[Empty name]" NAME="Keitel 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:09:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keitel W, Frerick H, Kuhn U, Schmidt U, Kuhlmann M, Bredehoorst A</AU>
<TI>Capsicum pain plaster in chronic non-specific low back pain</TI>
<SO>Arzneimittelforschung</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>11</NO>
<PG>896-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krivoy-2001" MODIFIED="2014-08-24 10:10:11 -0400" MODIFIED_BY="[Empty name]" NAME="Krivoy 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:10:11 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krivoy N, Pavlotzky E, Chrubasik S, Eisenberg E, Brook G</AU>
<TI>Effects of salicis cortex extract on human platelet aggregation</TI>
<SO>Planta Medica</SO>
<YR>2001</YR>
<VL>67</VL>
<NO>3</NO>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stam-2001" MODIFIED="2014-08-24 10:10:37 -0400" MODIFIED_BY="[Empty name]" NAME="Stam 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:10:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stam C, Bonnet MS, van Haselen RA</AU>
<TI>The efficacy and safety of a homeopathic gel in the treatment of acute low back pain: a multi-centre, randomised, double-blind comparative clinical trial</TI>
<SO>British Homeopathic Journal</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>1</NO>
<PG>21-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yip-2004" MODIFIED="2014-08-24 10:12:32 -0400" MODIFIED_BY="[Empty name]" NAME="Yip 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-24 10:12:32 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yip YB, Tse SHM</AU>
<TI>The effectiveness of relaxation acupoint stimulation and acupressure with aromatic lavender essential oil for non-specific low back pain in Hong Kong: a randomised controlled trial</TI>
<SO>Complementary Therapies in Medicine</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>1</NO>
<PG>28-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-12-18 13:42:19 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Blank-1970" MODIFIED="2014-08-24 10:13:41 -0400" MODIFIED_BY="[Empty name]" NAME="Blank 1970" YEAR="1970">
<REFERENCE MODIFIED="2014-08-24 10:13:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blank K</AU>
<TI>Observation on the hitherto little known use of opino-gel</TI>
<SO>Zeitschrift für Allgemeinmedizin</SO>
<YR>1970</YR>
<VL>46</VL>
<NO>17</NO>
<PG>893-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buttermann-2012" MODIFIED="2014-08-24 11:24:05 -0400" MODIFIED_BY="[Empty name]" NAME="Buttermann 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-24 11:24:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buttermann GR</AU>
<TI>Intradiscal injection therapy for degenerative chronic discogenic low back pain with end plate Modic changes</TI>
<SO>Spine Journal</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>2</NO>
<PG>176-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carragee-2011" MODIFIED="2014-08-24 10:15:08 -0400" MODIFIED_BY="[Empty name]" NAME="Carragee 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-24 10:15:08 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carragee EJ</AU>
<TI>Intradiscal treatment of back pain</TI>
<SO>Spine Journal</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>2</NO>
<PG>97-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2001b" MODIFIED="2014-08-24 10:29:17 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2001b" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:15:32 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Künzel O, Black A, Conradt C, Kerschbaumer F</AU>
<TI>Potential economic impact of using a proprietary willow bark extract in outpatient treatment of low back pain: an open non-randomized study</TI>
<SO>Phytomedicine</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>4</NO>
<PG>241-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2002a" MODIFIED="2014-08-24 10:30:21 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2002a" YEAR="2002">
<REFERENCE MODIFIED="2014-08-24 10:18:14 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Pollak S</AU>
<TI>Pain management with herbal antirheumatic drugs</TI>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>2002</YR>
<VL>152</VL>
<NO>7-8</NO>
<PG>198-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2002b" MODIFIED="2014-08-24 10:30:16 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2002b" YEAR="2002">
<REFERENCE MODIFIED="2014-08-24 10:17:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Pollak S, Conradt C</AU>
<TI>Clinical trial of willow bark extract. We have by no means compared apples and pears</TI>
<SO>MMW Fortschritte der Medizin</SO>
<YR>2002</YR>
<VL>144</VL>
<NO>9</NO>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2002c" MODIFIED="2014-09-02 19:02:09 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2002c" YEAR="2002">
<REFERENCE MODIFIED="2014-09-02 19:02:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Pollak S</AU>
<TI>Clinical trial of willow bark extract. We have by no means compared apples and pears.</TI>
<SO>MMW Fortschr Med</SO>
<YR>2002</YR>
<VL>144</VL>
<NO>9</NO>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2002d" MODIFIED="2014-08-24 10:38:58 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2002d" YEAR="2002">
<REFERENCE MODIFIED="2014-08-24 10:38:17 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Thanner J, Künzel O, Conradt C, Black A, Pollak S</AU>
<TI>Comparison of outcome measures during treatment with the proprietary Harpagophytum extract Doloteffin® in patients with pain in the lower back, knee or hip</TI>
<SO>Phytomedicine</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>3</NO>
<PG>181-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2004" MODIFIED="2014-08-24 10:21:05 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-24 10:21:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Frerick H</AU>
<TI>Treatment of chronic non-specific low back pain with Capsicum superior to placebo?</TI>
<SO>Focus on Alternative and Complementary Therapies</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>21-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2005" MODIFIED="2014-08-24 10:21:40 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-24 10:21:40 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Künzel O, Thanner J, Conradt J, Black A</AU>
<TI>A 1-year follow-up after a pilot study with Doloteffin for low back pain</TI>
<SO>Phytomedicine</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>1-2</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2006" MODIFIED="2014-08-24 10:22:43 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-08-24 10:22:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Chrubasik C, Wiesner L, Conradt C</AU>
<TI>Effectiveness and safety of a rose hip and seed powder in the treatment of low back pain</TI>
<SO>Focus on Alternative and Complementary Therapies</SO>
<YR>2006</YR>
<VL>11</VL>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2007" MODIFIED="2014-08-24 10:23:18 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-24 10:23:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik S, Chrubasik C, Künzel O, Black A</AU>
<TI>Patient-perceived benefit during one year of treatment with Doloteffin</TI>
<SO>Phytomedicine</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>6</NO>
<PG>371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chrubasik-2008" MODIFIED="2014-08-24 10:23:51 -0400" MODIFIED_BY="[Empty name]" NAME="Chrubasik 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-24 10:23:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chrubasik C, Wiesner L, Black A, Müller-Ladner U, Chrubasik S</AU>
<TI>A one-year survey on the use of a power from rosa canina lito in acute exacerbations of chronic pain</TI>
<SO>Phytotherapy Research</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corrigan-2005" MODIFIED="2014-08-24 10:24:25 -0400" MODIFIED_BY="[Empty name]" NAME="Corrigan 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-24 10:24:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corrigan D, Chrubasik S</AU>
<TI>Harpagophytum procumbens (devil's claw) extract for low back pain shows few adverse effects in 1-year follow-up</TI>
<SO>Focus on Alternative and Complementary Therapies</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>2</NO>
<PG>112-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gensthaler-2000" MODIFIED="2014-08-24 10:24:30 -0400" MODIFIED_BY="[Empty name]" NAME="Gensthaler 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-08-24 10:24:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gensthaler BM</AU>
<TI>Willow bark extract relieves low back pain</TI>
<SO>Pharmazeutische Zeitung</SO>
<YR>2000</YR>
<VL>145</VL>
<NO>48</NO>
<PG>41-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gobel-2001" MODIFIED="2014-08-24 10:26:19 -0400" MODIFIED_BY="[Empty name]" NAME="Gobel 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:26:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Göbel H, Heinze A, Ingwersen M, Niederberger U, Gerber D</AU>
<TI>Effects of Harpagophytum procumbens LI 174 (devil's claw) on sensory, motor und vascular muscle reagibility in the treatment of unspecific back pain</TI>
<SO>Schmerz</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>1</NO>
<PG>10-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-2007" MODIFIED="2014-08-24 10:26:29 -0400" MODIFIED_BY="[Empty name]" NAME="Hansen 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-24 10:26:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen TM, Hansen B</AU>
<TI>The effect of aromatherapy on health complaints. A randomised, controlled trial</TI>
<SO>International Journal of Essential Oil Therapeutics</SO>
<YR>2007</YR>
<VL>1</VL>
<NO>2</NO>
<PG>67-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harden-2000" MODIFIED="2014-08-24 10:27:38 -0400" MODIFIED_BY="[Empty name]" NAME="Harden 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-08-24 10:27:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harden RN, Argoff C</AU>
<TI>A review of three commonly prescribed skeletal muscle relaxants</TI>
<SO>Journal of Back and Musculoskeletal Rehabilitation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>2</NO>
<PG>63-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hemmil_x00e4_-1997" MODIFIED="2014-08-24 10:29:00 -0400" MODIFIED_BY="[Empty name]" NAME="Hemmilä 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-08-24 10:28:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hemmilä HM, Keinänen-Kiukaanniemi SM, Levoska S, Puska P</AU>
<TI>Does folk medicine work? A randomized clinical trial on patients with prolonged back pain</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>6</NO>
<PG>571-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogeboom-2001" MODIFIED="2014-08-24 10:31:12 -0400" MODIFIED_BY="[Empty name]" NAME="Hogeboom 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:31:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogeboom CJ, Sherman KJ, Cherkin DC</AU>
<TI>Variation in diagnosis and treatment of chronic low back pain by traditional Chinese medicine acupuncturists</TI>
<SO>Complementary Therapies in Medicine</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>154-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-1986" MODIFIED="2014-08-24 10:31:37 -0400" MODIFIED_BY="[Empty name]" NAME="Jiang 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-08-24 10:31:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang WZ, Zhou W, Zhao YG, Li YM, Zheng GC, Meng WC, et al</AU>
<TI>Treatment of discogenic back and leg pain based on differentiation of symptom-complex according to traditional Chinese medicine</TI>
<SO>Journal of Traditional Chinese Medicine</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>4</NO>
<PG>267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kong-2012" MODIFIED="2014-08-24 10:33:49 -0400" MODIFIED_BY="[Empty name]" NAME="Kong 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-24 10:33:49 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kong LJ, Fang M, Zhan HS, Yuan WA, Tao JM, Qi GW, et al</AU>
<TI>Chinese massage combined with herbal ointment for athletes with nonspecific low back pain: A randomized controlled trial</TI>
<SO>Evidence-based Complementary and Alternative Medicine</SO>
<YR>2012</YR>
<VL>2012</VL>
<PG>695726</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kucera-2005" MODIFIED="2014-08-24 10:34:51 -0400" MODIFIED_BY="[Empty name]" NAME="Kucera 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-24 10:34:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kucera M, Barna M, Horàcek O, Kàlal J, Kucera A, HladÌkova M</AU>
<TI>Topical symphytum herb concentrate cream against myalgia: a randomized controlled double-blind clinical study</TI>
<SO>Advances in Therapy</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>6</NO>
<PG>681-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laudahn-2001a" MODIFIED="2014-08-24 10:39:31 -0400" MODIFIED_BY="[Empty name]" NAME="Laudahn 2001a" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:39:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laudahn D, Walper A</AU>
<TI>Efficacy and tolerance of Harpagophytum extract LI 174 in patients with chronic non-radicular back pain</TI>
<SO>Phytotherapy Research</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>7</NO>
<PG>621-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2012" MODIFIED="2014-08-24 10:42:20 -0400" MODIFIED_BY="[Empty name]" NAME="Lee 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-24 10:42:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee S, Lee J</AU>
<TI>Randomized double blinded clinical trial of Ojeoksan products extracted through different methods for low back pain. Scientific Abstracts Presented at the International Research Congress on Integrative Medicine and Health 2012</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>Suppl 1</NO>
<PG>P189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2013" MODIFIED="2014-08-24 10:42:33 -0400" MODIFIED_BY="[Empty name]" NAME="Liu 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-24 10:42:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu WN, Gan HR, Fang CZ</AU>
<TI>Shoulder back lumbar pain treated with application with argy wormwood feeleaf volatile oil</TI>
<SO>Zhongguo Zhenjiu</SO>
<YR>2013</YR>
<VL>33</VL>
<NO>2</NO>
<PG>171-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00e4_rz-2002" MODIFIED="2014-08-24 10:44:08 -0400" MODIFIED_BY="[Empty name]" NAME="März 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-24 10:43:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>März RW, Kemper F</AU>
<TI>Willow bark extract--effects and effectiveness. Status of current knowledge regarding pharmacology, toxicology and clinical aspects</TI>
<SO>Wiener Medizinische Wochenschrift</SO>
<YR>2002</YR>
<VL>152</VL>
<NO>15-16</NO>
<PG>354-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NASSBD-2003" MODIFIED="2014-08-24 10:45:01 -0400" MODIFIED_BY="[Empty name]" NAME="NASSBD 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-24 10:45:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>North American Spine Society Board of Directors</AU>
<TI>Spine Patient Outcome Research Trial (SPORT): multi-center randomized clinical trial of surgical and non-surgical approaches to the treatment of low back pain</TI>
<SO>Spine Journal</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>6</NO>
<PG>417-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pabst-2013" MODIFIED="2014-08-24 10:45:38 -0400" MODIFIED_BY="[Empty name]" NAME="Pabst 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-24 10:45:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pabst H, Schaefer A, Staiger C, Junker-Samek M, Predel HG</AU>
<TI>Combination of comfrey root extract plus methyl nicotinate in patients with conditions of acute upper or low back pain: a multicentre randomised controlled trial</TI>
<SO>Phytotherapy Research</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>6</NO>
<PG>811-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pach-2011" MODIFIED="2014-08-24 10:46:24 -0400" MODIFIED_BY="[Empty name]" NAME="Pach 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-24 10:46:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pach D, Brinkhaus B, Roll S, Wegscheider K, Icke K, Willich SN, et al</AU>
<TI>Efficacy of injections with Disci/Rhus toxicodendron compositum for chronic low back pain--a randomized placebo-controlled trial</TI>
<SO>PLoS One</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>11</NO>
<PG>e26166</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reme-2011" MODIFIED="2014-08-24 10:47:23 -0400" MODIFIED_BY="[Empty name]" NAME="Reme 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-24 10:47:23 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reme SE, Tveito TH, Chalder T, Bjørkkjaer T, Indahl A, Brox JI, et al</AU>
<TI>Protocol for the Cognitive Interventions and Nutritional Supplements (CINS) trial: a randomized controlled multicenter trial of a brief intervention (BI) versus a BI plus cognitive behavioral treatment (CBT) versus nutritional supplements for patients with long-lasting muscle and back pain</TI>
<SO>BMC Musculoskeletal Disorders</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-2005" MODIFIED="2014-08-24 10:50:45 -0400" MODIFIED_BY="[Empty name]" NAME="Schmidt 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-24 10:50:45 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt A, Berghof U, Schmidt E</AU>
<TI>Effectiveness of harpagophytum procumbens in treatment of unspecific low back pain</TI>
<TO>Therapie der unspezifischen Lumbalgie mit Teufelskrallenwurzelextrakt - Ergebnisse einer klinischen Studie</TO>
<SO>Physikalische Medizin Rehabilitationsmedikin Kurortmedizin</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>5</NO>
<PG>317-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherman-2001a" MODIFIED="2014-08-24 10:51:44 -0400" MODIFIED_BY="[Empty name]" NAME="Sherman 2001a" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:51:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman KJ, Hogeboom CJ, Cherkin DC</AU>
<TI>How traditional Chinese medicine acupuncturists would diagnose and treat chronic low back pain: results of a survey of licensed acupuncturists in Washington State</TI>
<SO>Complementary Therapies in Medicine</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>146-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherman-2001b" MODIFIED="2014-08-24 10:52:14 -0400" MODIFIED_BY="[Empty name]" NAME="Sherman 2001b" YEAR="2001">
<REFERENCE MODIFIED="2014-08-24 10:52:14 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman KJ, Cherkin DC, Hogeboom CJ</AU>
<TI>The diagnosis and treatment of patients with chronic low-back pain by traditional Chinese medical acupuncturists</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>6</NO>
<PG>641-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takabayashi-1990" MODIFIED="2014-08-24 10:53:04 -0400" MODIFIED_BY="[Empty name]" NAME="Takabayashi 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-08-24 10:53:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takabayashi T, Sasaki H, Shintaku Y, Sasamoto K, Ozawa N, Hamazaki Y, et al</AU>
<TI>Effects of a medicinal herbal liqueur, "yomeishu", on post-operative gynecological patients</TI>
<SO>American Journal of Chinese Medicine</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>1-2</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tant-2005" MODIFIED="2014-08-24 10:53:29 -0400" MODIFIED_BY="[Empty name]" NAME="Tant 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-24 10:53:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tant L, Gillard B, Appelboom T</AU>
<TI>Open-label, randomized, controlled pilot study of the effects of a glucosamine complex on low back pain</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>6</NO>
<PG>511-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uehleke-2013" MODIFIED="2014-12-18 13:42:19 -0500" MODIFIED_BY="[Empty name]" NAME="Uehleke 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-18 13:42:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uehleke B, Muller J, Stange R, Kelber O, Melzer J</AU>
<TI>Willow bark extract STW-33-I in the long term treatment of outpatients with rheumatic pain mainly osteoarthritis or back pain</TI>
<SO>Phytomedicine</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>11</NO>
<PG>980-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ukhalkar-2013" MODIFIED="2014-08-24 10:53:43 -0400" MODIFIED_BY="[Empty name]" NAME="Ukhalkar 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-24 10:53:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ukhalkar VP</AU>
<TI>Effect of mashadi tailam anuvasan basti in management of kativata with special reference to lumbar spondylosis</TI>
<SO>International Journal of Research in Ayurveda and Pharmacy</SO>
<YR>2013</YR>
<VL>4</VL>
<NO>3</NO>
<PG>410-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wimmer-1997" MODIFIED="2014-08-24 10:55:29 -0400" MODIFIED_BY="[Empty name]" NAME="Wimmer 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-08-24 10:55:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wimmer C, Ogon M, Sterzinger W, Landauer F, Stöckl B</AU>
<TI>Conservative treatment of tuberculous spondylitis: a long-term follow-up study</TI>
<SO>Journal of Spinal Disorders</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>5</NO>
<PG>417-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-1993" MODIFIED="2014-08-24 10:55:34 -0400" MODIFIED_BY="[Empty name]" NAME="Xu 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-08-24 10:55:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu JH, Cui L, Jia BH</AU>
<TI>Effect of tonifying kidney on compliability of the aged</TI>
<SO>Zhongguo Zhong Xi Yi Jie He Za Zhi</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>4</NO>
<PG>208-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2013" MODIFIED="2014-08-24 11:24:13 -0400" MODIFIED_BY="[Empty name]" NAME="Yuan 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-08-24 11:24:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan WA, Huang SR, Guo K, Sun WQ, Xi XB, Zhang MC, et al</AU>
<TI>Integrative TCM conservative therapy for low back pain due to lumbar disc herniation: A randomized controlled clinical trial</TI>
<SO>Evidence-based Complementary and Alternative Medicine</SO>
<YR>2013</YR>
<VL>June 24</VL>
<PG>Epub</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-12-18 13:41:07 -0500" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-12-05 13:40:19 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-12-05 13:40:19 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Blumenthal-1998" NAME="Blumenthal 1998" TYPE="BOOK">
<AU>Blumenthal M (Ed.)</AU>
<SO>The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines</SO>
<YR>1998</YR>
<PB>American Botanical Council</PB>
<CY>Austin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bombardier-2011" MODIFIED="2014-08-24 11:01:07 -0400" MODIFIED_BY="[Empty name]" NAME="Bombardier 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bombardier C, van Tulder MW, Bronfort G, Chou R, Corbin T, Deyo RA, et al</AU>
<TI>Cochrane Back Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</SO>
<YR>2011</YR>
<VL>2011</VL>
<NO>4</NO>
<PG>n/a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boutron-2005" MODIFIED="2014-08-24 11:01:42 -0400" MODIFIED_BY="[Empty name]" NAME="Boutron 2005" TYPE="JOURNAL_ARTICLE">
<AU>Boutron I, Moher D, Tugwell P, Giraudeau B, Poiraudeau S, Nizard R, et al</AU>
<TI>A checklist to evaluate a report of a non pharmacological trial (CLEAR NPT) was developed using consensus</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2005</YR>
<VL>58</VL>
<NO>12</NO>
<PG>1233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deyo-2006" MODIFIED="2014-08-24 11:02:07 -0400" MODIFIED_BY="[Empty name]" NAME="Deyo 2006" TYPE="JOURNAL_ARTICLE">
<AU>Deyo RA, Mirza SK, Martin BI</AU>
<TI>Back pain prevalence and visit rates</TI>
<SO>Spine</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>23</NO>
<PG>2724-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duffy-2014" MODIFIED="2014-12-05 13:40:19 -0500" MODIFIED_BY="[Empty name]" NAME="Duffy 2014" TYPE="OTHER">
<AU>Duffy S, Misso K, Noake C, Ross J, Stirk L</AU>
<TI>Supplementary searches of PubMed to improve currency of MEDLINE and MEDLINE In-Process searches via OvidSP</TI>
<SO>Kleijnen Systematic Reviews Ltd, York.
</SO>
<YR>Poster presented at the UK InterTASC Information Specialists' Sub-Group (ISSG) Workshop; 9 July 2014; Exeter: UK (2014) [accessed 6.8.14]. Available from: https://medicine.exeter.ac.uk/media/universityofexeter/medicalschool/research/pentag/documents/Steven_Duffy_ISSG_Exeter_2014_poster_1.pdf</YR>
<IDENTIFIERS MODIFIED="2014-10-01 15:56:02 -0400" MODIFIED_BY="Shireen Harbin"/>
</REFERENCE>
<REFERENCE ID="REF-Eisenberg-2012" MODIFIED="2014-08-24 11:02:59 -0400" MODIFIED_BY="[Empty name]" NAME="Eisenberg 2012" TYPE="JOURNAL_ARTICLE">
<AU>Eisenberg DM, Buring JE, Hrbek AL, Davis RB, Connelly MT, Cherkin DC, et al</AU>
<TI>A model of integrative care for low-back pain</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>4</NO>
<PG>354-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frass-2012" MODIFIED="2014-08-24 11:03:43 -0400" MODIFIED_BY="[Empty name]" NAME="Frass 2012" TYPE="JOURNAL_ARTICLE">
<AU>Frass M, Strassl RP, Friehs H, Müllner M, Kundi M, Kaye AD</AU>
<TI>Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review</TI>
<SO>Ochsner Journal</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>1</NO>
<PG>45-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedley-2010" MODIFIED="2014-08-24 11:04:42 -0400" MODIFIED_BY="[Empty name]" NAME="Friedley 2010" TYPE="JOURNAL_ARTICLE">
<AU>Friedley J, Standaert C, Chan L</AU>
<TI>Epidemiology of spine care: the back pain dilemma</TI>
<SO>Physical Medicine and Rehabilitation Clinics of North America</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>4</NO>
<PG>659-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2010" MODIFIED="2014-08-24 11:05:36 -0400" MODIFIED_BY="[Empty name]" NAME="Friedman 2010" TYPE="JOURNAL_ARTICLE">
<AU>Friedman BW, Chilstrom M, Bijur PE, Gallagher EJ</AU>
<TI>Diagnostic testing and treatment of low back pain in United States emergency departments: a national perspective</TI>
<SO>Spine</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>24</NO>
<PG>E1406-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furlan-2009" MODIFIED="2014-08-24 11:06:28 -0400" MODIFIED_BY="[Empty name]" NAME="Furlan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Furlan AD, Pennick V, Bombardier C, van Tulder M; Editorial Board, Cochrane Back Review Group</AU>
<TI>2009 Updated method guidelines for systematic reviews in the Cochrane Back Review Group</TI>
<SO>Spine</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>18</NO>
<PG>1929-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gagnier-2006a" MODIFIED="2014-08-24 11:06:34 -0400" MODIFIED_BY="[Empty name]" NAME="Gagnier 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Gagnier JJ, DeMelo J, Boon H, Rochon P, Bombardier C</AU>
<TI>Quality of reporting of randomized controlled trials of herbal interventions</TI>
<SO>American Journal of Medicine</SO>
<YR>2006</YR>
<VL>119</VL>
<NO>9</NO>
<PG>800.e1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gagnier-2006b" MODIFIED="2014-08-24 11:07:37 -0400" MODIFIED_BY="[Empty name]" NAME="Gagnier 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group</AU>
<TI>Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2006</YR>
<VL>144</VL>
<NO>5</NO>
<PG>364-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gagnier-2006c" MODIFIED="2014-08-24 11:08:16 -0400" MODIFIED_BY="[Empty name]" NAME="Gagnier 2006c" TYPE="JOURNAL_ARTICLE">
<AU>Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group</AU>
<TI>Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>11</NO>
<PG>1134-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grabois-2005" MODIFIED="2014-08-24 11:09:01 -0400" MODIFIED_BY="[Empty name]" NAME="Grabois 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grabois M</AU>
<TI>Management of chronic low back pain</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>3 Suppl</NO>
<PG>S29-S41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2004" MODIFIED="2014-08-24 11:11:03 -0400" MODIFIED_BY="[Empty name]" NAME="GRADE 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haldeman-2008" MODIFIED="2014-08-24 11:11:36 -0400" MODIFIED_BY="[Empty name]" NAME="Haldeman 2008" TYPE="JOURNAL_ARTICLE">
<AU>Haldeman S, Dagenais S</AU>
<TI>What have we learned about the evidence-informed management of chronic low back pain?</TI>
<SO>Spine Journal</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>266-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-08-24 11:12:01 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huwiler_x002d_Muntener-2002" MODIFIED="2014-08-24 11:13:48 -0400" MODIFIED_BY="[Empty name]" NAME="Huwiler-Muntener 2002" TYPE="JOURNAL_ARTICLE">
<AU>Huwiler-Müntener K, Jüni P, Junker C, Egger M</AU>
<TI>Quality of reporting of randomized trials as a measure of methodologic quality</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>21</NO>
<PG>2801-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koes-2006" MODIFIED="2014-08-24 11:14:41 -0400" MODIFIED_BY="[Empty name]" NAME="Koes 2006" TYPE="JOURNAL_ARTICLE">
<AU>Koes BW, van Tulder MW, Thomas S</AU>
<TI>Diagnosis and treatment of low back pain</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<NO>7555</NO>
<PG>1430-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krivoy-2000" MODIFIED="2014-08-24 11:15:17 -0400" MODIFIED_BY="[Empty name]" NAME="Krivoy 2000" TYPE="JOURNAL_ARTICLE">
<AU>Krivoy N, Pavlotzky E, Chrubasik S, Eisenberg E, Brook G</AU>
<TI>Effects of salicis cortex extract on human platelet aggregation</TI>
<SO>Planta Medica</SO>
<YR>2000</YR>
<VL>67</VL>
<NO>3</NO>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manniche-1994" MODIFIED="2014-08-24 11:16:07 -0400" MODIFIED_BY="[Empty name]" NAME="Manniche 1994" TYPE="JOURNAL_ARTICLE">
<AU>Manniche C, Asmussen K, Lauritsen B, Vinterberg H, Kreiner S, Jordan A</AU>
<TI>Low Back Pain Rating scale: validation of a tool for assessment of low back pain</TI>
<SO>Pain</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>3</NO>
<PG>317-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metcalfe-2010" MODIFIED="2014-08-24 11:16:48 -0400" MODIFIED_BY="[Empty name]" NAME="Metcalfe 2010" TYPE="JOURNAL_ARTICLE">
<AU>Metcalfe A, Williams J, McChesney J, Patten SB, Jetté N</AU>
<TI>Use of complementary and alternative medicine by those with a chronic disease and the general population - results of a national population based survey</TI>
<SO>BMC Complementary &amp; Alternative Medicine</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mills-2000" NAME="Mills 2000" TYPE="BOOK">
<AU>Mills S, Bone K</AU>
<SO>Principles and Practice of Phytotherapy: Modern Herbal Medicine</SO>
<YR>1999</YR>
<PB>Churchill Livingston</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mills-2002" MODIFIED="2014-08-24 11:17:58 -0400" MODIFIED_BY="[Empty name]" NAME="Mills 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mills EJ, Hollyer T, Guyatt G, Ross CP, Saranchuk R, Wilson K; Evidence-based Complementary and Alternative Medicine Working Group</AU>
<TI>Teaching evidence-based complementary and alternative medicine: 1. A learning structure for clinical decision changes</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>2</NO>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2014-08-24 11:19:27 -0400" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Jones A, Lepage L; CONSORT Group (Consolidated Standards for Reporting of Trials)</AU>
<TI>Use of the CONSORT statement and quality of reports of randomized trials: a comparative before and after evaluation</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1992-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2012" MODIFIED="2014-08-24 11:20:17 -0400" MODIFIED_BY="[Empty name]" NAME="Moher 2012" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>International Journal of Surgery</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>1</NO>
<PG>28-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mounce-2002" MODIFIED="2014-08-24 11:20:39 -0400" MODIFIED_BY="[Empty name]" NAME="Mounce 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mounce K</AU>
<TI>Back pain (editorial)</TI>
<SO>Rheumatology</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" MODIFIED="2014-08-24 11:21:23 -0400" MODIFIED_BY="[Empty name]" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K</AU>
<TI>Development of a highly sensitive strategy for the retrieval of reports of controlled trials using PubMed</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>150-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sierpina-2002" MODIFIED="2014-08-24 11:21:52 -0400" MODIFIED_BY="[Empty name]" NAME="Sierpina 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sierpina V</AU>
<TI>Progress notes: A review of educational developments in CAM</TI>
<SO>Alternative Therapies in Health and Medicine</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>6</NO>
<PG>104-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Tulder-2003" MODIFIED="2014-08-24 11:22:46 -0400" MODIFIED_BY="[Empty name]" NAME="van Tulder 2003" TYPE="JOURNAL_ARTICLE">
<AU>van Tulder M, Furlan A, Bombardier C, Bouter L; Editorial Board of the Cochrane Collaboration Back Review Group</AU>
<TI>Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group</TI>
<SO>Spine</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>12</NO>
<PG>1290-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vickers-2000" MODIFIED="2014-08-24 11:23:21 -0400" MODIFIED_BY="[Empty name]" NAME="Vickers 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vickers A</AU>
<TI>Recent advances: complementary medicine</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<NO>7262</NO>
<PG>683-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waddell-1996" MODIFIED="2014-08-24 11:23:44 -0400" MODIFIED_BY="[Empty name]" NAME="Waddell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Waddell G</AU>
<TI>Low back pain: a twentieth century health-care enigma</TI>
<SO>Spine</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>24</NO>
<PG>2820-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-09-02 18:45:15 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gagnier-2002" MODIFIED="2014-09-02 18:45:13 -0400" MODIFIED_BY="[Empty name]" NAME="Gagnier 2002" TYPE="COCHRANE_REVIEW">
<AU>Gagnier JJ, vanTulder M, Berman B, Bombardier C</AU>
<TI>Herbal medicine for low back pain.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-09-02 18:43:13 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-02 18:43:13 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-12-18 13:43:24 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-08-27 20:52:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-1996">
<CHAR_METHODS MODIFIED="2014-08-27 20:52:41 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups. Patients were placed in groups by random number allocation. Period: Four weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:52:41 -0400" MODIFIED_BY="[Empty name]">
<P>118 participants were allocated to a <I>H. procumbens </I>(H) group (N = 59) and a placebo (P) group (N = 59)and 109 participants completed the trial (H; N = 54; P; N = 55). Inclusion criteria: participants were between 18 to 75 years of age, had at least six months of LBP not attributable to identifiable causes, were suffering from acute increases in pain, and were expected to require at least four weeks of symptomatic treatment. Exclusion criteria: participation in other clinical studies or had done so within the past 30 days, pregnancy, lactation, insufficient contraception, difficulties with language or cooperation, known allergy to proposed trial medication, history of drug or alcohol abuse, requirement of psychotherapeutic agents, or a serious organic illness affecting any of the organ systems.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:52:41 -0400" MODIFIED_BY="[Empty name]">
<P>Oral form of <I>H. procumbens </I>(devil's claw) standardized to a dosage of 50 mg harpagoside per day or 2400 mg of the crude extract.<BR/>Matched placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:52:41 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: cumulative requirement for Tramadol (an oral opiate-based analgesic) over the last three weeks of the study period. Secondary: number of pain free patients based on a five-point visual rating scale and the Arhus LBP index.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 20:52:41 -0400" MODIFIED_BY="[Empty name]">
<P>Total Quality Score: 7/12<BR/>Adverse events: four adverse effects occurred in the <I>H. procumbens</I> group with only two potentially due to the treatment (i.e. repeated coughs and tachycardia). A total of 10 adverse events occurred in the P group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 20:55:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-1999">
<CHAR_METHODS MODIFIED="2014-08-27 20:54:28 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with three groups. Period: four weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:55:14 -0400" MODIFIED_BY="[Empty name]">
<P>One hundred and ninety-seven participants allocated to <I>H. procumbens </I>at 600 mg (N = 65), or 1200 mg (N = 66) or matched placebo (N = 66).</P>
<P>Inclusion criteria: 18 to 75 years of age, six months of non-specific LBP, a current exacerbation of their complaint that was effecting both rest and movement, which was giving rise to pain greater than five on a 1-10 VAS and was expected to require at least four weeks of symptomatic treatment. Exclusion criteria: current or recent participation in any other clinical study, serious organic illness effecting any organ system, a history of drug or alcohol abuse or requirement for psychotherapeutic agents, pregnancy (actual or possible), or lactation, known allergy to any the proposed trial medications, difficulties with language or anticipated co-operation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:55:23 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>H. procumbens</I> extract WS 1531 600 mg (50 mg harpagoside), 1200 mg (100 mg harpagoside)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:55:32 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: proportion of pain-free participants without Tramadol for at least five days during the last week of treatment. Secondary outcomes: Arhus index, percentage requiring Tramadol, verbal pain ratings.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 20:55:40 -0400" MODIFIED_BY="[Empty name]">
<P>Total Quality Score: 8/12<BR/>Adverse effects included: nine participants with gastrointestinal upset (four in each active group and one in the placebo group)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-02 18:24:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2000">
<CHAR_METHODS MODIFIED="2014-08-27 20:56:02 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with three groups. No report of randomization method. Period: four weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:56:18 -0400" MODIFIED_BY="[Empty name]">
<P>Participants were recruited from the Haifa area in Israel between May and November. Two hundred and ten participants were randomized into three groups (N = 70 in each group) and 191 completed the trial (P; N = 59; 120; N = 67; 240; N = 65).<BR/>Inclusion criteria: Between 18 and 75 years of age, at least six months of intermittent LBP that was not attributable to identifiable causes, a current exacerbation of their complaint at rest and with movement that caused pain of at least five out of 10 on a VAS, and that was expected to require at least four weeks of treatment. Exclusion criteria: participation in other clinical studies or had done so in past 30 days, pregnancy, lactation, insufficient contraception, difficulties with language or cooperation, known allergy to proposed trial medication, history of drug or alcohol abuse, requirement of psychotherapeutic agents</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:56:32 -0400" MODIFIED_BY="[Empty name]">
<P>Extract of dry willow bark (<I>S. alba</I>): 120 mg salicin, 240 mg salicin. Matched placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:56:36 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: the proportion of participants who responded to treatment by being pain free without Tramadol for at least five days during the last week of treatment. Secondary outcome: The Arhus LBP Index scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-02 18:24:43 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 7/12<BR/>Adverse events: one adverse reaction (exanthem, swollen eyes, pruritis) could be attributed to the 120 mg willow bark extract group. A total of two participants in the 240 mg group reported short lasting adverse events (dizziness attributed to Tramadol, dizziness and fatigue). These patients dropped-out for seemingly unrelated reasons. Six adverse events were reported in the placebo group including three attributable to Tramadol (dizziness or headache; dizziness, vomiting ordiarrhoea; dry mouth) and the three others reported mild abdominal pain, two of whom dropped out on the first day of the trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 20:57:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2001a">
<CHAR_METHODS MODIFIED="2014-08-27 20:57:56 -0400" MODIFIED_BY="[Empty name]">
<P>Open RCT with two groups comparing an herbal medicine (<I>S. alba</I>) to a synthetic anti-rheumatic (rofecoxib).<BR/>Period: four weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:57:56 -0400" MODIFIED_BY="[Empty name]">
<P>228 participants divided equally in to two groups (N = 114 per group).<BR/>Inclusion criteria: age 18 to 80, at least six months non-specific LBP.<BR/>Exclusion criteria: recent trauma, a history of cancer or risk factors for spinal infection, unexplained weight loss or recent fever or chills, pain exacerbated by being supine or severe nocturnal pain, perineal anaesthesia, recent onset of bladder dysfunction or severe progressive neurological deficit in the lower extremity, recent participation in other clinical trial, serious organic illness affecting any organ system, a history of drug or alcohol abuse or requirement for psychotherapeutic drugs, pregnancy or lactation, known allergy to salicylates, difficulties with language or expected corporation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:57:56 -0400" MODIFIED_BY="[Empty name]">
<P>A proprietary extract of <I>S. alba</I> called Assalix at four capsules per day providing a total of 240 mg of salicin per day, or a single 12.5 mg tablet of rofecoxib per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:57:57 -0400" MODIFIED_BY="[Empty name]">
<P>Pain on a VAS, modified Arhus index, its pain component and the total pain index, physician and patient-rated success and the acceptability of the treatment on a verbal scale (very good, good, moderate, poor).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 20:57:57 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 6/12<BR/>Adverse events: 23 in the <I>S. alba</I> group (13 of gastrointestinal (GI) origin, five cutaneous allergy, remaining undefined), and 27 in the rofecoxib group (17 GI effects, one asthma, the remainder undefined). Trial authors judged GI adverse events as more severe and caused more withdrawals in the rofecoxib group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-02 16:42:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2003">
<CHAR_METHODS MODIFIED="2014-08-27 20:58:26 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups. Period: six weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:58:26 -0400" MODIFIED_BY="[Empty name]">
<P>88 participants allocated to <I>H. procubens</I> (N = 44) group or rofecoxib (N = 44).<BR/>Inclusion criteria: age 45 to 75, at least six months of non-specific LBP, current exacerbation of complaints for eight weeks that was affecting both rest and movement, was causing pain of at least five out of 10 on a VAS and judged to require symptomatic treatment for six weeks. Exclusion criteria: red flags for LBP, participation in any other clinical study within the last 30 days, serious organic illness affecting any organ system, a history of drug or alcohol abuse or requirement of psychotherapeutic drugs, pregnancy or lactation, known allergies to trial medication, and anticipated difficulties with language or corporation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:58:26 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>H. procumbens</I> in a proprietary aqueous extract called Doloteffin (standardized to contain 60 mg harpagoside) or 12.5 mg rofecoxib per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:58:26 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: proportion of participants who recorded "no pain" without using Tramadol for at least five days in the final week or treatment. Secondary and other outcomes: proportion of patients in whom the averaged daily pain scores in the 6th week had decreased by 20 to 50% of the average in the first week; the percentage change from baseline of a modified Arhus LBP index; the percentage change from baseline on the Health Assessment Questionnaire; Tramadol requirement.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-02 16:42:20 -0400" MODIFIED_BY="[Empty name]">
<P>Total Quality Score: 8/12<BR/>Adverse effects: 14 participants in each group. GI: eight in the devil's claw group, nine in the Vioxx® group which tended to be more severe. Two serious adverse events occurred in the devil's claw group but were judged unrelated to the trial medication. Circulatory and laboratory variables were not affected by either treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 20:58:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2010">
<CHAR_METHODS MODIFIED="2014-08-27 20:58:50 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups. Participants were placed in groups by computerized randomization list. Period: three weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:58:50 -0400" MODIFIED_BY="[Empty name]">
<P>Two hundred and eighty-two participants were allocated to Finalgon® CPD Warmecreme (a capsicum-containing cream) (N = 140), or matched placebo (N = 141). Inclusion criteria: aged between 18 and 65 years, Caucasian, chronic pain of the soft tissues of the musculoskeletal apparatus, subjective pain at enrolment &#8805; 5 (VAS 0&#8211;10; 0, no pain; 10, intolerable pain), ability and expressed willingness of the patient to follow the investigator&#8217;s instructions, i.e. meeting the prerequisites of the study, applying study medication according to the dosage regimen and filling in the questionnaires at the control visits, and granting of written informed consent.</P>
<P>Exclusion criteria:</P>
<P>severe co-morbidity, addiction to alcohol or other drugs, pregnancy and lactation, insufficient contraceptive protection, participation in another clinical trial within the past four weeks, concomitant psychiatric disorders, a surgical procedure required in the immediate future, inability of the patient to understand the nature, importance and consequences of the study, muscle rupture, vertebral disk prolapse, spondylolisthesis, spinal canal stenosis, known or clinically proven instability of the spine, spinal fractures, tumours, infections, inflammatory joint conditions, seronegative spondyloarthropathies, osteoporosis as the cause of pain, chronic skin diseases, known hypersensitivity to capsaicin or other ingredients of the cream, anxiety or depressive conditions, &#8805; 11 points of anxiety or depression scores (Hamilton Anxiety Depression Scale).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:58:50 -0400" MODIFIED_BY="[Empty name]">
<P>'Finalgon® CPD Wärmecreme', of which 100 g contain 2.2 to 2.6 g soft extract of <I>Capsici fructus acer</I> corresponding to 53 mg capsaicin (0.05%), applied as a thin layer thrice daily over a three week period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:58:50 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: treatment response, defined as pain sum score reduction &#8805; 30%. Secondary outcomes: median relative pain sum score improvement, average pain in the last 24 hours, worst pain in the past three days, average pain in the past three days, pain intensity at the moment of maximum pain relief, the delay between the application of cream and the onset of maximum effect, the duration of analgesia, efficacy as determined by the investigator (excellent, good, adequate, unsatisfactory) and patient (free of complaints, symptoms improved, unchanged, worsened).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 20:58:50 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 7/12</P>
<P>Adverse effects: three patients in the treatment group experienced adverse effects and none in the placebo group. In the treatment group, these included unpleasant local heat sensation in two participants and pruritus in one participant.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 20:59:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-da-Silva-2010">
<CHAR_METHODS MODIFIED="2013-05-23 11:34:25 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups. Period: 15 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:59:10 -0400" MODIFIED_BY="[Empty name]">
<P>Twenty participants allocated to Brazilian arnica gel (N = 10) or placebo gel (N = 10). Inclusion criteria: No specific criteria listed. Patient recruitment was based on spontaneous demand for treating lumbago within the academic community at UVV/ES and was accompanied by the physiotherapy clinic. All participants went through a screening process coordinated by the physiotherapist responsible for the orthopaedics, traumatology, and rheumatology sector of the clinic. After screening, participants were submitted to medical evaluations to diagnose the nature of their lumbago before being allowed to participate in the research program. Exclusion criteria: volunteers under 18 were not permitted to participate in the program, unless they had their parent's or legal guardian's permission, people who were not in otherwise good physical and/or mental condition, who did not pass the screening process, who were eliminated as a result of diagnoses made by the physiotherapy sector, or pregnant women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:59:10 -0400" MODIFIED_BY="[Empty name]">
<P>5% concentrated plant extract from aerial vegetative and reproductive parts of <I>S. chilensis </I>Meyen, diluted in propylene glycol and added at a proportion of 5% (w/v) in carbomer gel, corresponding to active substances in 5 g of dry raw material. 10 g of the placebo or arnica gels was manually and uniformly applied on the area of the lesion twice daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 16:01:53 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Change in perception of pain by VAS. Secondary outcome: lumbar flexibility, as determined by the modified Schober method</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 16:02:46 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 5/12</P>
<P>Adverse effects: nothing reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-02 16:42:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frerick-2003">
<CHAR_METHODS MODIFIED="2014-08-27 20:59:28 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups. Period: three weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:59:28 -0400" MODIFIED_BY="[Empty name]">
<P>Three hundred and twenty participants with chronic non-specific LBP divided equally between capsicum plaster group and placebo group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:59:28 -0400" MODIFIED_BY="[Empty name]">
<P>Topical plaster containing an ethonolic extract of cayenne pepper standardized to 22 µg/cm<SUP>2</SUP> of capsaicinoinds or placebo plaster</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:59:28 -0400" MODIFIED_BY="[Empty name]">
<P>Outcomes: Arhus LBP Rating Scale, global assessment of efficacy by patient and investigator, global assessment of safety by patient and investigator.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-02 16:42:31 -0400" MODIFIED_BY="[Empty name]">
<P>Total Quality Score: 6/12<BR/>Adverse effects: 14 participants in each group. GI: 8 in the devil's claw group, 9 in the Vioxx® group which tended to be more severe. Two serious adverse events occurred in the devil's claw group but were judged unrelated to the trial medication. Circulatory and laboratory variables were not affected by either treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 20:59:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannetti-2010">
<CHAR_METHODS MODIFIED="2014-08-27 20:59:48 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups. Period: five days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 20:59:48 -0400" MODIFIED_BY="[Empty name]">
<P>120 patients allocated to Kytta-Salbe (a cream containing Comfrey root extract) (N = 60) or a matched placebo cream (N = 60). Inclusion criteria: Age range 18 to 60 years, good general condition, written informed consent, acute back pain (either upper or lower back pain) not in combination, sensitivity to algometric pressure on the site contralateral to the painful trigger point at least 2.5 N/cm<SUP>2</SUP>, basic value of the pressure algometry on the trigger point shall not exceed 50% of the respective value of the site contralateral to the painful trigger point.</P>
<P>Exclusion criteria: upper or lower back pain that is attributable to any identifiable cause, any recent trauma, any recent strains of the back muscles documented by clinical evaluation and anamnesis, chronic back pain, diabetes mellitus, risk factors for spinal infection, recent onset of bladder dysfunction or severe or progressive neurological deficit in the low extremity (as a possible indication of prolapsed disc), concomitant use of any anti-inflammatory drugs, heparinoids or analgesics, including herbal preparations (glucocorticosteroids, NSAID, etc) for the same indication or other indications (e.g. rheumatoid arthritis), analgesics or NSAID applied by any route of administration within 10 days of study entry or corticoid drugs applied by any route of administration within 60 days of study entry, any other concomitant treatment or medication that interferes with the conduct of the trial, known intolerance or hypersensitivity (allergy) to the trial treatments, including known toxic reactions, local skin infections that do not allow the application of the test ointment, participation in a clinical trial within the previous 30 days before enrolment in the trial, participation in this study before or simultaneous participation in another clinical trial, pregnancy or lactation period, women with childbearing potential without an effective contraceptive method, abuse of alcohol, medicaments or illicit drugs, any patient in the investigator&#8217;s opinion not considered suitable for enrolment, legal incapacity or limited legal capacity to give informed consent.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 20:59:48 -0400" MODIFIED_BY="[Empty name]">
<P>Kytta-Salbe f. 100 g contains 35 g 99% PA reduced Rad symphyti fluid extract. Four grams were applied topically, administered three times a day at intervals of approximately eight hours and continued for five days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 20:59:48 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Area under the curve (AUC) of the VAS values on active standardized movement. Secondary outcomes: AUC of back pain at rest by VAS, AUC over five days of pressure algometry values, global assessment of efficacy by the patients, global assessment of efficacy by the investigators.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 20:59:48 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 8/12</P>
<P>Adverse effects: four participants in the treatment group and three participants in the placebo group experienced adverse effects. In the treatment group, two participants experienced headaches and one participant experienced pruritus. In the control group, participants experienced eczema, cold, nausea, and rhinitis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 21:00:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ginsberg-1987">
<CHAR_METHODS MODIFIED="2014-08-27 21:00:07 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with 40 patients assigned to one of twp groups for period of 14 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 21:00:07 -0400" MODIFIED_BY="[Empty name]">
<P>Forty participants with acute mechanical LBP were assigned to either the Rado-Salil (a capsicum-containing cream) group (N = 20) or a placebo group (N = 20). Each patient was also given 45 paracetamol 250 mg tablets. No other analgesic, anti-inflammatory drug or physical treatment was allowed during the 12-week period.<BR/>Method of participants selection: clinical examination, standard radiological examination of the lumber spine, routine laboratory tests.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 21:00:07 -0400" MODIFIED_BY="[Empty name]">
<P>Rado-Salil ointment (containing 17.64 mg ethysalicylate, 26.47 mg methylsalicylate, 8.82 mg glycosalicylate, 8.82 mg salicylic acid, 4.41 mg camphor, 55.14 mg menthol, and 15.44 mg Capsicum Oleoresin per 1 g) in the form of a 40 g stick applied as needed or a placebo (containing only the excipient with three times the amount of lavendula and bergamot essences) matched for appearance.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes: pain evaluation on a 10 cm linear scale, duration of confinement to bed, muscular reflex contracture evaluation by the physician on a scale of 0 to 4, and spine mobility by determination of Schober's index, the finger to floor distance, the degree of lumbar extension, global appreciation of treatment by patient and physician.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 21:00:07 -0400" MODIFIED_BY="[Empty name]">
<P>Total Quality Score: 5/12<BR/>Adverse events: pruritis, one in placebo, one in Rado-Salil group. Local erythema and burning, three in the Rado-Salil group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 21:00:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keitel-2001">
<CHAR_METHODS MODIFIED="2014-08-27 21:00:57 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups. No report of randomization method. Period: one plaster per day at maximum pain site for four to 12 hours for three weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 21:00:57 -0400" MODIFIED_BY="[Empty name]">
<P>One hundred and fifty-four participants were randomly allocated to a placebo plaster group (N = 77) and a capsicum plaster group (N = 77). A total of 132 participants completed the study, with data available for the intention to treat (ITT) analysis on 150 participants (P = 0.002). A total 22 participants were excluded due to premature discontinuation of the treatment (N = 19) failure to meet the inclusion criteria (N = 2) or unauthorized concurrent treatment (N = 1). Inclusion criteria: subjective back pain rating of five or more on an 11 grade VAS, as well as a duration of back pain for a minimum of three months at enrolment. Exclusion criteria: alcohol abuse, drug dependence, forms of specific back pain, concomitant systemic inflammatory rheumatic condition, no concurrent therapy for back pain.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 21:00:57 -0400" MODIFIED_BY="[Empty name]">
<P>Topical plaster type application of <I>C. frutescens</I> (cayenne) containing 12 mg of capsaicinoids per plaster. Matched placebo plaster.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome measure: Arhus Low Back Rating Scale. Secondary outcome measures: global assessment of efficacy and tolerance by physician and patient.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 21:00:57 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 6/12<BR/>Adverse events: a total of 24 adverse events were reported (C = 15; P = 9). Most of these were warmth and itching locally. The C group had five cases of severe adverse events (inflammatory contact eczema, urticaria, minute haemorrhagic spots, and vesiculation or dermatitis) and the P group had two such cases (vesiculation or allergic dermatosis). A total of 16 participants withdrew because of adverse events (C = 10; P = 6). Also, 95.9% of the C group and 48.7% of the P group experienced sensations of warmth locally. Pruritis was mentioned in 45.9% of the C group and 31.6% of the P group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 21:01:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krivoy-2001">
<CHAR_METHODS MODIFIED="2014-08-27 21:01:24 -0400" MODIFIED_BY="[Empty name]">
<P>Thirty-five participants randomized to two groups and a further 16 participants acted as controls. Period: four weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 21:01:24 -0400" MODIFIED_BY="[Empty name]">
<P>Fifty-one participants with 19 in the <I>Salix alba</I> group, 16 in a placebo group, and 16 in an acetylsalicylate group.<BR/>Inclusion criteria: acute exacerbations of chronic LBP, stable ischemic heart disease. Exclusion criteria: NSAID use.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 21:01:24 -0400" MODIFIED_BY="[Empty name]">
<P>786.48 mg twice per day of an ethanol extract of the bark of <I>Salix daphnoides</I> (240 mg salicin content per day), matched placebo, or 100 mg acetylsalicylate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: platelet aggregation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Total quality score: 5/12<BR/>Adverse events: none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 21:01:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stam-2001">
<CHAR_METHODS MODIFIED="2014-08-27 21:01:48 -0400" MODIFIED_BY="[Empty name]">
<P>RCT with two groups (no placebo). Randomization was performed using RCODE software (Version 3.4) in blocks of four. Period: seven days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 21:01:48 -0400" MODIFIED_BY="[Empty name]">
<P>One hundred and sixty-one participants were randomly allocated to either group. A total of six participants were lost to follow-up (SLR = 2; CCC = 4). Twenty-one participants met all per protocol criteria. Inclusion criteria: between the ages of 18 and 65, acute attack of LBP within previous 72 hours, free from back pain during the previous three months, at least moderately painful limitation of movement on physical examination. Exclusion criteria: radicular symptoms, pain above T12, rheumatoid arthritis, ankylosing spondylitis, known hypersensitivity to treatment compounds, use of analgesics other than paracetamol during the treatment period, use of NSAIDs during the treatment period, receiving other treatment for acute LBP, pregnancy, over 96 hours elapsed since onset of pain, including washout for analgesic or NSAIDs or both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 21:01:48 -0400" MODIFIED_BY="[Empty name]">
<P>Spiroflor SLR homeopathic gel (SLR) group (N = 83) or CCC group (N = 78). Each gel was applied at 3 g per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-27 21:01:48 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: reduction in VAS scores for pain (100 mm scale) and the proportion of treatment success (a VAS reduction of at least 80%). Secondary outcome measures: proportion of participants using paracetamol, number of nights with disturbed sleep, duration of absence from work and an overall assessments of treatment efficacy or usefulness by the general practitioners (GP) and the patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-27 21:01:48 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 9/12.<BR/>Adverse Events: Approximately 12% of SLR and 26% of the CCC group experienced an adverse event. Adverse drug reactions were reported by 4% of the SLR group and 24% of the CCC group. A total of four adverse drug reactions in the CCC group and none in the SLR group were considered "severe". A total of eight participants in the CCC group and 0 participants in the SLR group withdrew due to adverse drug reactions.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-27 21:02:05 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yip-2004">
<CHAR_METHODS MODIFIED="2014-08-27 21:02:05 -0400" MODIFIED_BY="[Empty name]">
<P>Unblinded RCT with two groups. Period: three weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 21:02:05 -0400" MODIFIED_BY="[Empty name]">
<P>Sixty-one patients were allocated to acupressure with lavender oil (N = 32) or conventional treatment (N = 29). Inclusion criteria: aged 18 or above with non-specific sub-acute LBP for most days in the past four weeks; who had not received acupuncture, physiotherapy, or manipulative therapy in the past week; who could understand the explanation of the study, complete the interview and comprehend the instructions. Non-specific sub-acute LBP was defined as pain on most days in the past four weeks, in the area between the lower coastal margins and the gluteal folds without known specific cause, such as a spinal deformity. Exclusion criteria: LBP caused by specific entities, such as infection, metastases, neoplasm osteoporosis, fractures, spine deformity, or prolapsed intervertebral disc; had undergone surgery or had dislocation, fracture, neurological deficits, spinal disease, varicose vein, blood dyscrasia, cancer or systemic disorders; were pregnant; were allergic to natural lavender aromatic oil; had a wound at any of the acupoints at the back or on the lower limb; or had had a surgical intervention within the last three months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 21:02:05 -0400" MODIFIED_BY="[Empty name]">
<P>Acupoint stimulation with a digital Electronic Muscle Stimulator for 10 minutes, followed by acupressure massage, consisting of the application of a light to medium finger press with 3% aromatic natural lavender oil with grape seed oil as the base on eight fixed acupoints for two minutes each. Treatment lasted 35 to 40 minutes and occurred eight times over a three-week period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-23 11:28:58 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Pain intensity rating on VAS. Secondary outcomes: range of motion of lateral spine flexion, quantified by lateral fingertip-to-ground distance, walking time for 15 meters, interference with daily activities measured by the modified Aberdeen LBP scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-23 11:29:06 -0400" MODIFIED_BY="[Empty name]">
<P>Total quality score: 4/12</P>
<P>Adverse effects: Reported no adverse effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-12-18 13:43:24 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:02:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blank-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:02:35 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:02:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buttermann-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:02:39 -0400" MODIFIED_BY="[Empty name]">
<P>Did not study non-specific LBP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:02:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carragee-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:02:50 -0400" MODIFIED_BY="[Empty name]">
<P>Note on another article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:22 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:19 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:13 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2002c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:08 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:02:59 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2002d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:02:59 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-02 18:49:25 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-02 18:49:25 -0400" MODIFIED_BY="[Empty name]">
<P>Comment on another study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:38 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:43 -0400" MODIFIED_BY="[Empty name]">
<P>Abstract from a symposium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:48 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chrubasik-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:51 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-02 18:32:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corrigan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-02 18:32:40 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:03:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gensthaler-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:03:57 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gobel-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:00 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hansen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>Did not study LBP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harden-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:08 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hemmil_x00e4_-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:13 -0400" MODIFIED_BY="[Empty name]">
<P>Not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hogeboom-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:21 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT, not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kong-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kucera-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Did not study LBP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laudahn-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Conference abstract only, unknown participants type, unknown if a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Abstract or full text not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00e4_rz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:49:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NASSBD-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:49:52 -0400" MODIFIED_BY="[Empty name]">
<P>Comment on another article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pabst-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Mixed low back and upper back pain with no subgroup analyses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-02 18:33:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pach-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-02 18:33:18 -0400" MODIFIED_BY="[Empty name]">
<P>Herbal medicine given by injection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reme-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sherman-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT, not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sherman-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT, not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takabayashi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not LBP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tant-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Did not use herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-18 13:43:24 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uehleke-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-18 13:43:24 -0500" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ukhalkar-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not an oral or topical route of administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wimmer-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not LBP, not a herbal medicine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuan-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-27 21:04:31 -0400" MODIFIED_BY="[Empty name]">
<P>Not LBP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-12-18 13:41:07 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:53:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Participants were placed in groups by random number allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:34:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Randomization was conducted via stratified random allocation based on informed consent sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:35:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Three group randomized double-blind study with randomization conducted by "computerized list" but no further details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:36:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Randomization completed by pre-determined computer-generated random sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:36:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>Prospective, randomized, double-blind, double-dummy study with randomization via assigned random number. No further description of the randomization process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 12:44:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Randomization completed by computerized randomization list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 13:35:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>Randomization was computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:58 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:00:16 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>The exact method used for randomization was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>No report of randomization method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-26 13:01:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Randomization process not defined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Randomization was performed using RCODE software (version 3.4) in blocks of four.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:02:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Participants were allocated by the research team consulting a random numbers table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>No method of randomization described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:31:05 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Further description beyond randomized allocation is not included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:34:45 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>No additional information provided beyond randomization method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:57:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:58:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Group allocation concealed prior to the start of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:36:45 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>Not enough information in the text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>Allocation was done by external personnel not involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:58 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-26 09:35:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 18:49:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-26 13:01:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Allocation concealment was adequate, providers were not influential in group selection.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-26 15:03:52 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Patients and clinicians were aware of group allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>All outcomes - outcome assessors?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes - patients?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes - providers?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:53:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Treatment group assignment blinded to participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 20:54:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Treatment group assignment blinded to providers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-03-25 11:31:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Blinding done and unlikely the blinding was broken.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-25 11:34:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Treatment allocation blinded to participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-03-25 11:34:45 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Treatment allocation blinded to providers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 20:55:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Treatment allocation blinded to both participants and providers and not likely broken. Treatment and placebo medications identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:57:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Participants were given identical coded tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-03-25 11:35:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Investigators were blinded from the medication coding scheme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 20:57:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Treatment allocation blinded to both participants and providers and not likely broken. Treatment and placebo medications identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:58:13 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Participants only blinded to group allocation until after enrolment were non-blinded at study start.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-03-25 11:36:06 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Providers not blinded to group allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-03-25 11:36:06 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>The only blinded provider was an independent reviewer for adverse outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>The trial is described as a double blind double-dummy RCT. However, there is very little description of the blinding in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>The trial is described as a double blind double-dummy RCT. However, there is very little description of the blinding in the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>It is unclear if participants were blinded to the intervention medication or just the accompanying placebo. However if the study medication is unblinded it should not incur unacceptable bias into the outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Participants were randomized to treatment groups with intervention and placebo medications identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-03-25 12:44:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Outcome assessment unblinded but unlikely to influence outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>Participants were blinded to study group, and study medication and placebo were identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 20:59:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>Providers were blinded to study group and study medication and placebo were identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:59:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>The trial medication and placebo ointments were similar in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 20:59:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>The clinicians were blinded to treatment group. However, there is little description of care taken to disguise the intervention or placebo ointment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 20:59:58 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 21:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Participants were given either a treatment ointment or a placebo that are identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 21:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 21:00:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Outcome assessments unblinded but unlikely to influence outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 21:01:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>Study medication and placebo were identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 21:01:17 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 21:01:17 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 21:01:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Participants were blinded from treatment group allocation, and study medication and placebo were identical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 21:01:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Providers were blinded from treatment group allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 21:01:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Outcome assessors were unblinded. However knowing the outcome of interest, platelet aggregation, is unlikely to effect outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Participants were blinded to treatment group and although trial medications were not identical, they were packed in identical containers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Providers were blinded to group allocation and were only able to access treatment group allocation if there was an adverse event which required unblinding. The trial medications were not available to the providers in the trial country at the time and all stakeholders assumed both medications held active ingredients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>This was a double-blinded trial. While there were reservations with the blinding due to non-similar medications, there was no evidence that unblinding occurred.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 21:02:25 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Intervention treatment and control treatment were dissimilar with no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-08-27 21:02:13 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Providers were aware and involved in the treatment allocation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 21:02:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>Participants were blinded to treatment group and were unaware of which compound was being applied.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-03-25 13:07:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>Providers were blinded to treatment group and were unaware of which compound was being applied.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" NO="11">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" NO="12">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes - drop-outs?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes - ITT analysis?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:53:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Only nine participants were lost to attrition, with the remaining 109 participants completing all outcome measures. Missing data not related to outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:54:08 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Treatment group had four participants not complete the final examination and one suffered tachycardia; the control group had four participants not complete the final examination, but participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:55:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>All participants completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:55:55 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:57:20 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>191 participants out of 210 completed baseline and final outcome measures. Analysis was conducted with and without drop-out data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:57:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:58:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Forty-five participants were disenrolled prior to the trial conclusion, leaving 183 participants which allows adequate number of participants per group. The PAID group lost 21 participants (five due to non-compliance, one for severe LBP, and 12 due to adverse events), the NSAID group lost 24 participants (six for non-compliance, three for severe LBP, three for other pain reasons, and 14 to adverse events).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:58:13 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>Of the 88 participants who enrolled, nine participants dropped out. This should not significantly impact the outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>There were seven participants who withdrew during the course of the study, six from the treatment group (three due to symptom abatement, two for insufficient pain relief and one for refusal to continue) and one from the placebo group due to symptom abatement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>There were seventy withdrawals in the course of the trial, which resulted in a reduction of 319 participants to 249 participants. Despite the withdrawals, the study groups remained balanced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:59:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>All participants completed baseline to end of study measures.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:59:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 21:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>No withdrawals noted in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 21:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 21:01:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>Out of 154 participants, 22 were excluded due to premature discontinuation of treatment (N = 19, failure to meet exclusion criteria (N = 2), and unauthorized outside treatment (N = 1). Of the remaining 132 participants the groups maintained adequately balanced.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 21:01:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-26 13:07:51 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>There were no withdrawals noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 21:01:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>One hundred and fifty-four out of 161 participants were able to provide evaluable results from baseline to seven days.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 21:02:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Of the 61 original participants, 10 participants dropped out but there was no difference in dropout rate between groups. Reasons for withdrawal by participants were not related to study procedures and should have little effect on outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 21:02:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>No loss to follow-up noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>Participants appeared to be analysed in the groups to which they were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Similarity of baseline characteristics?</NAME>
<DESCRIPTION>
<P>Were the groups similar at baseline regarding the most important prognostic indicators?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:54:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>No significant difference within baseline characteristics between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:34:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Groups were well matched for age, height, weight, and gender and of 120 matched indicators only four would have reached statistical significance in single isolated comparisons.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:35:25 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Baseline characteristics were similar across all three groups only differing on six reported factors out of 110.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:36:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Similarity between groups at baseline was adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>Baseline characteristics of participants between groups was similar with no significant differences noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Baseline characteristics of participants between groups was similar with no significant differences noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>With the exception of slightly more female participants in the placebo group, the groups were comparable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>Groups were well balanced at baseline, with slightly more female participants than males.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>Apart from a slightly higher BMI in the placebo group the groups were comparable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>The groups were similar in baseline measures except gender; there were more female participants in the placebo group (P = 0.01).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Group comparison was similar with no significant differences noted between groups at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:02:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>No significant differences between study groups noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>There were no significant differences noted in baseline comparisons between the placebo and intervention group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Co-interventions avoided or similar?</NAME>
<DESCRIPTION>
<P>Were co-interventions avoided or similar?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:54:23 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 18:49:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:57:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:58:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Participants were allowed to continue with current medications, or current alternative treatments and therapies, or both.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>Participants were allowed to supplement the trial medications with Tramadol liquid. However, this was used as an additional outcome measure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>No co-interventions noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>No co-interventions noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>No co-interventions noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Participants were given paracetamol tablets in addition to study medication or placebo. No other medication or physical treatment was allowed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-26 10:28:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>No co-intervention noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Participants were disallowed the use of anti-inflammatory drugs within the trial period. Tramadol was allowed as an emergency medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Anti-inflammatory drugs were disallowed during the trial phase with paracetamol used as an emergency medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:02:16 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>No discussion or controlling for medication or additional treatment modalities noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Compliance acceptable?</NAME>
<DESCRIPTION>
<P>Was the compliance acceptable in all groups?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:54:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 18:49:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:57:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:58:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>No issues regarding compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>No issues regarding compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>No issues with compliance noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>Poor compliance was noted among participants. Rapid improvement and three applications per day may have influenced non-compliance. Compliance was equal across groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:02:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>Unclear from text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 13:16:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>No issued noted with compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Timing outcome assessments similar?</NAME>
<DESCRIPTION>
<P>Was the timing of the outcome assessment in all groups similar?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:31:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:34:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 18:49:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:36:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 12:05:36 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 15:48:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:00:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>Unclear from text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:02:16 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>There was no description of the control group's therapy beyond being a conventional therapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>No differences noted in timing.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2014-12-16 09:51:50 -0500" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Selective Reporting</NAME>
<DESCRIPTION>
<P>Reporting bias</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:31:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1996">
<DESCRIPTION>
<P>All prespecified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:34:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-1999">
<DESCRIPTION>
<P>All prespecified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:35:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2000">
<DESCRIPTION>
<P>All prespecified outcomes data and analyses was available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 11:36:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2001a">
<DESCRIPTION>
<P>All prespecified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:58:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2003">
<DESCRIPTION>
<P>All prespecified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chrubasik-2010">
<DESCRIPTION>
<P>All prespecified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frerick-2003">
<DESCRIPTION>
<P>All pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannetti-2010">
<DESCRIPTION>
<P>All pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:00:17 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ginsberg-1987">
<DESCRIPTION>
<P>No comparison of groups noted and certain baseline measures were not reported in the final results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keitel-2001">
<DESCRIPTION>
<P>All pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krivoy-2001">
<DESCRIPTION>
<P>All pre-specified measures were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:01:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stam-2001">
<DESCRIPTION>
<P>All pre-specified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 21:02:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yip-2004">
<DESCRIPTION>
<P>All pre-specified outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-27 20:59:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-da-Silva-2010">
<DESCRIPTION>
<P>Outcome measures were straightforward with pre-specified outcomes being reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-12-16 10:05:56 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-12-16 10:01:05 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-12-16 10:01:05 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 1: Brazilian arnica extract compared to placebo for patients with non-specific chronic back pain or soft tissue pain</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Brazilian arnica extract compared to placebo for patients with non-specific chronic back pain or soft tissue pain</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with back pain</P>
<P>
<B>Settings: </B>outpatient clinic</P>
<P>
<B>Intervention: </B>extract of Brazilian arnica</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain reduction based on</P>
<P>Pain VAS instrument 0-100 scale</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20<BR/>(one trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Very small sample size only N = 10 in the treatment group. This trial found that topical application of Brazilian arnica reduced the perception of pain and increased flexibility in the treated group compared to baseline values in that group. Unknown if acute or chronic LBP.</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Selection bias was high to unclear, performance bias was low risk to unclear risk, with other attributes being low risk.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-12-16 10:05:56 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-12-16 10:01:14 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 2: Topical capsaicin cream or plaster compared to placebo for patients with non-specific chronic back pain or soft tissue pain</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Topical capsaicin cream or plaster compared to placebo for patients with non-specific chronic back pain or soft tissue pain</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with chronic LBP or soft tissue pain</P>
<P>
<B>Settings: </B>Outpatient clinic</P>
<P>
<B>Intervention: </B>topical capsicum cream or plaster</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain perception according to the Pain VAS scale</P>
<P>0-10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>755<BR/>(three trials)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All three trials found a statistically significant difference between</P>
<P>the capsaicin intervention vs. placebo. In three trials minor adverse effects were noted in the treatment groups requiring no specific follow-up treatments.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>All three trials exhibited low to unclear risk in selection bias, performance bias and attrition bias. One trial was at high risk for selective reporting.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2014-12-16 10:02:22 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-12-16 10:02:22 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 3: Topical capsaicin cream compared with placebo for patients with acute non-specific LBP</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Topical capsaicin cream compared with placebo for patients with acute non-specific LBP</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with acute mechanical LBP</P>
<P>
<B>Settings: </B>outpatient clinic</P>
<P>
<B>Intervention: </B>Rado-Salil ointment</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain evaluation on a 10 cm linear scale</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
<P>(one trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain improvements were significantly greater in the capsicum cream group up to day 14. Adverse events: Pruritis, one in placebo, one in Rado-Salil group. Local erythema and burning, three in the Rado-Salil group.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Exhibited unclear risk for selection bias as well unclear baseline similarities. Performance bias was low risk as was attrition bias but it was high risk for incomplete outcome data.</P>
<P>
<SUP>2</SUP>As under 400 participants were included, evidence was downgraded to very low from low.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2014-12-16 10:02:34 -0500" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-12-16 10:02:34 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 4: <I>H. procumbens</I> compared to placebo for non-specific chronic back pain</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<I>
<B>H. procumbens</B>
</I>
<B> compared to placebo for non-specific chronic back pain</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with chronic back pain</P>
<P>
<B>Settings: </B>outpatient clinic</P>
<P>
<B>Intervention:</B> <I>H. procumbens</I> extract</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Arhus pain index</P>
<P>scale 0-130</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>315<BR/>(two trials)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>In one trial a 50mg dose of <I>H. procumbens</I> was used, and in</P>
<P>the second trial a 50 mg and 100 mg dose was used with both trialss</P>
<P>showing a significantly improved pain score over placebo.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Both included trials exhibited low risk of bias regarding selection bias with one trial at unclear risk of bias. Performance bias was at low risk of bias, as was attrition bias with one trial at high risk of bias for incomplete outcome data.</P>
<P>
<I>2</I>Two trials included under 400 participants and we downgraded the evidence to low from moderate.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2014-12-16 10:02:52 -0500" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-12-16 10:02:52 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 5: <I>H. procumbens </I>extract compared to Vioxx® for non-specific chronic LBP</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<I>
<B>H. procumbens </B>
</I>
<B>extract compared to Vioxx</B>®<B> for non-specific chronic LBP</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with chronic LBP</P>
<P>
<B>Settings: </B>outpatient clinic</P>
<P>
<B>Intervention: </B>
<I>H. procumbens</I> extract</P>
<P>
<B>Comparison: </B>Vioxx®</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Modified Arhus Index</P>
<P>Scale 0-120</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>88<BR/>(one trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>H. procumbens</I> was compared to Vioxx®</P>
<P>and while both groups showed similar pain reduction scores there were no</P>
<P>demonstrable difference among groups. There were adverse effects noted in both</P>
<P>groups.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>This trial was at low risk of bias for all risk of bias factors, with the exception of allocation concealment and compliance which were at unclear risk of bias.</P>
<P>
<SUP>2</SUP>Downgraded to very low versus low as under 400 participants were included.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2014-12-16 10:03:50 -0500" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-12-16 10:03:50 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 6: Willow bark extract compared to placebo for non-specific chronic LBP</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Willow bark extract compared to placebo for non-specific chronic LBP</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with chronic LBP</P>
<P>
<B>Settings: </B>outpatient clinic and public advertisement</P>
<P>
<B>Intervention: </B>willow bark extract</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain VAS</P>
<P>Scale 0-10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>261<BR/>(two trials)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The high dose (240 mg) treatment group</P>
<P>showed a significant reduction in pain</P>
<P>scores versus the low dose (120 mg) group</P>
<P>and the placebo group. There was one severe</P>
<P>allergic reaction related to the extract noted.</P>
<P>One trial (N = 51) also examined the effect of</P>
<P>the extract on platelet aggregation.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Both trials were at low to unclear risk for selection bias, low risk for performance bias with one trial exhibiting high risk in baseline characteristics similarity. Both trials were rated as an overall low risk of bias since they met our predetermined cut-point of 50% of the criteria on which the trial methods were assessed. </P>
<P>
<SUP>2</SUP>Downgraded from high to moderate as under 400 participants were included between both trials.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2014-12-16 10:04:01 -0500" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2014-12-16 10:04:01 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 7: Willow bark extract compared to rofecoxib for non-specific chronic LBP</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Willow bark extract compared to rofecoxib for non-specific chronic LBP</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with chronic LBP</P>
<P>
<B>Settings: </B>outpatient clinic</P>
<P>
<B>Intervention: </B>willow bark extract</P>
<P>
<B>Comparison: </B>rofecoxib</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(one trial)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Arhus Index</P>
<P>Scale 0-130</P>
<P/>
<P>Pain VAS</P>
<P>Scale 0-10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>228<BR/>(one trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>There was no significant difference</P>
<P>in the effectiveness and adverse</P>
<P>events between the extract and</P>
<P>rofecoxib.</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Low risk for selection bias, high risk for performance bias, and high and low risk for attrition bias.</P>
<P>
<SUP>2</SUP>Downgraded from low to very low due as under 400 participants were included.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2014-12-16 10:04:12 -0500" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2014-12-16 10:04:12 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 8: Comfrey root extract compared to placebo for acute lower and upper back non-specific pain</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Comfrey root extract compared to placebo for acute lower and upper back non-specific pain</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with acute lower and upper back pain</P>
<P>
<B>Settings: </B>outpatient setting</P>
<P>
<B>Intervention: </B>comfrey root extract</P>
<P>
<B>Comparison:</B> placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain VAS sum (decrease) on active standardized</P>
<P>movement (mm)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>120<BR/>(one trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The root extract showed a statistically</P>
<P>and clinically relevant reduction in</P>
<P>acute back pain versus placebo.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Unclear risk for selection bias, low risk for both performance and attrition bias.</P>
<P>
<SUP>2</SUP>Downgraded from moderate to low as under 400 participants were included.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-09" MODIFIED="2014-12-16 10:04:22 -0500" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2014-12-16 10:04:22 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 9: Lavender oil acupressure massage and acupoint stimulation compared to usual treatment for acute non-specific LBP</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Lavender oil acupressure massage and acupoint stimulation compared to usual treatment for acute non-specific LBP</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with acute LBP</P>
<P>
<B>Settings: </B>old aged home and community centre</P>
<P>
<B>Intervention: </B>lavender oil massage</P>
<P>
<B>Comparison: </B>usual therapy</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain VAS</P>
<P>0-10 scale</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61<BR/>(one trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>One week post-study the treatment group</P>
<P>showed a significant (P = 0.0001) reduction</P>
<P>in VAS pain as well as improved walking time</P>
<P>and lateral spine flexion range.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Sequence generation was at low risk of bias but allocation concealment was at high risk. Performance bias was at high and unclear risk. Co-interventions and timing outcome assessment factors were at high risk of bias.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-10" MODIFIED="2014-12-16 10:04:31 -0500" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2014-12-16 10:04:31 -0500" MODIFIED_BY="[Empty name]">Summary of findings table 10: Spiroflor SRL compared to CCC for chronic non-specific LBP</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Spiroflor SRL compared to CCC for chronic non-specific LBP</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>patients with acute and chronic LBP</P>
<P>
<B>Settings: </B>outpatient clinic</P>
<P>
<B>Intervention: </B>Spiroflor SRL</P>
<P>
<B>Comparison: </B>CCC</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pain VAS</P>
<P>0-100 scale</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>161<BR/>(one trial)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Spiroflor SRL and CCC were equally effective in</P>
<P>treating acute LBP but the CCC</P>
<P>group experienced greater adverse events</P>
<P>and adverse drug reactions.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CCC = Cremor Capsici Compositus FNA; SRL = Homeopathic combination of <I>Symphytum officinale, Rhus toxicodendron</I> and <I>Ledum palustre</I>
</P>
<P>
<SUP>1</SUP>All risk of bias factors were at low risk of bias, except patient compliance which was at high risk.</P>
<P>
<SUP>2</SUP>Downgraded from low to very low as under 400 participants were included.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-12-04 16:10:04 -0500" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-12-16 09:51:52 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-12-16 09:51:52 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Summary of risk of bias for each of the included trials.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeAAAAOLCAIAAAAHGsdyAABBrUlEQVR42u3dsY4TS9r/cUtIiGAC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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-12-18 11:51:32 -0500" MODIFIED_BY="Shireen Harbin">
<APPENDIX ID="APP-01" MODIFIED="2014-12-18 11:50:54 -0500" MODIFIED_BY="Shireen Harbin" NO="1">
<TITLE MODIFIED="2014-12-18 08:59:47 -0500" MODIFIED_BY="Shireen Harbin">Current search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-12-18 11:50:54 -0500" MODIFIED_BY="Shireen Harbin">
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>Randomized Controlled Trials/</LI>
<LI>Random Allocation/</LI>
<LI>Double-Blind Method/</LI>
<LI>Single-Blind Method/</LI>
<LI>or/1-6</LI>
<LI>Animals/ not Human/</LI>
<LI>7 not 8</LI>
<LI>clinical trial.pt.</LI>
<LI>exp Clinical Trial/</LI>
<LI>(clin$ adj25 trial$).tw.</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.</LI>
<LI>Placebos/</LI>
<LI>placebo$.tw.</LI>
<LI>random$.tw.</LI>
<LI>Research Design/</LI>
<LI>(latin adj square).tw.</LI>
<LI>or/10-18</LI>
<LI>19 not 18</LI>
<LI>20 not 9</LI>
<LI>Comparative Study/</LI>
<LI>exp Evaluation Studies/</LI>
<LI>Follow-Up Studies/</LI>
<LI>Prospective Studies/</LI>
<LI>(control$ or prospective$ or Volunteer$).tw.</LI>
<LI>Cross-Over Studies/</LI>
<LI>or/22-27</LI>
<LI>28 not 8</LI>
<LI>29 not (9 or 21)</LI>
<LI>9 or 21 or 30</LI>
<LI>dorsalgia.ti,ab.</LI>
<LI>exp Back Pain/</LI>
<LI>backache.ti,ab.</LI>
<LI>(lumbar adj pain).ti,ab.</LI>
<LI>coccyx.ti,ab.</LI>
<LI>coccydynia.ti,ab.</LI>
<LI>sciatica.ti,ab.</LI>
<LI>sciatic neuropathy/</LI>
<LI>spondylosis.ti,ab.</LI>
<LI>lumbago.ti,ab.</LI>
<LI>or/32-41</LI>
<LI>31 and 42</LI>
<LI>Drugs, Chinese Herbal/</LI>
<LI>herbal.mp.</LI>
<LI>Plants, Medicinal/</LI>
<LI>phytomedicine.mp.</LI>
<LI>herb$.mp.</LI>
<LI>weed.mp.</LI>
<LI>algae.mp.</LI>
<LI>cryptophyta/ or haptophyta/ or exp glaucophyta/ or exp rhodophyta/ or exp viridiplantae/ or exp chlorophyta/ or exp streptophyta/ or exp stramenopiles/</LI>
<LI>exp Fungi/</LI>
<LI>exp Medicine, Traditional/</LI>
<LI>exp Phytotherapy/</LI>
<LI>exp Pharmacognosy/</LI>
<LI>(oriental adj traditional).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</LI>
<LI>(Camphora adj molmol).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</LI>
<LI>Capsicum/</LI>
<LI>exp Salicaceae/</LI>
<LI>(Maleluca adj alternifolia).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</LI>
<LI>Angelica sinensis/</LI>
<LI>Aloe/</LI>
<LI>(Thymus adj officinalis).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</LI>
<LI>Menthe piperita.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</LI>
<LI>Arnica Montana.mp. or Arnica/</LI>
<LI>Curcuma longa.mp. or Curcuma/</LI>
<LI>Tanacetum parthenium.mp. or Tanacetum parthenium/</LI>
<LI>feverfew.mp.</LI>
<LI>Harpagophytum procumbens.mp. or exp Harpagophytum/</LI>
<LI>Zingiber officii.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</LI>
<LI>plant preparations/ or plant extracts/ or plant oils/</LI>
<LI>or/44-71</LI>
<LI>43 and 72</LI>
<LI>31 and 42 and 72</LI>
<LI>limit 74 to yr=2013-Current</LI>
<LI>limit 74 to ed=20130806-20140911</LI>
<LI>75 or 76</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>From the 2013 strategy, line 31 was changed from 14 and 30 to 14 or 30</P>
<OL>
<LI>Clinical Article/</LI>
<LI>exp Clinical Study/</LI>
<LI>Clinical Trial/</LI>
<LI>Controlled Study/</LI>
<LI>Randomized Controlled Trial/</LI>
<LI>Major Clinical Study/</LI>
<LI>Double Blind Procedure/</LI>
<LI>Multicenter Study/</LI>
<LI>Single Blind Procedure/</LI>
<LI>Phase 3 Clinical Trial/</LI>
<LI>Phase 4 Clinical Trial/</LI>
<LI>crossover procedure/</LI>
<LI>placebo/</LI>
<LI>or/1-13</LI>
<LI>allocat$.mp.</LI>
<LI>assign$.mp.</LI>
<LI>blind$.mp.</LI>
<LI>(clinic$ adj25 (study or trial)).mp.</LI>
<LI>compar$.mp.</LI>
<LI>control$.mp.</LI>
<LI>cross?over.mp.</LI>
<LI>factorial$.mp.</LI>
<LI>follow?up.mp.</LI>
<LI>placebo$.mp.</LI>
<LI>prospectiv$.mp.</LI>
<LI>random$.mp.</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.</LI>
<LI>trial.mp.</LI>
<LI>(versus or vs).mp.</LI>
<LI>or/15-29</LI>
<LI>14 or 30</LI>
<LI>exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/</LI>
<LI>human/ or normal human/ or human cell/</LI>
<LI>32 and 33</LI>
<LI>32 not 34</LI>
<LI>31 not 35</LI>
<LI>dorsalgia.mp.</LI>
<LI>back pain.mp.</LI>
<LI>exp BACKACHE/</LI>
<LI>(lumbar adj pain).mp.</LI>
<LI>coccyx.mp.</LI>
<LI>coccydynia.mp.</LI>
<LI>sciatica.mp.</LI>
<LI>exp ISCHIALGIA/</LI>
<LI>spondylosis.mp.</LI>
<LI>lumbago.mp.</LI>
<LI>exp Low back pain/</LI>
<LI>or/37-47</LI>
<LI>exp herbaceous agent/</LI>
<LI>herbal.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</LI>
<LI>exp medicinal plant/</LI>
<LI>exp phytotherapy/</LI>
<LI>exp herbal medicine/</LI>
<LI>phytomedicine.mp.</LI>
<LI>exp plant extract/</LI>
<LI>herb*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</LI>
<LI>weed.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</LI>
<LI>exp alga/</LI>
<LI>exp fungus/</LI>
<LI>exp traditional medicine/</LI>
<LI>exp pharmacognosy/</LI>
<LI>(oriental adj traditional).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</LI>
<LI>exp Chinese medicine/</LI>
<LI>exp pepper/</LI>
<LI>capsicum.mp.</LI>
<LI>exp willow/</LI>
<LI>salix.mp.</LI>
<LI>exp Angelica sinensis/</LI>
<LI>exp Aloe/</LI>
<LI>exp Arnica montana/</LI>
<LI>exp Curcuma longa/</LI>
<LI>tanacetum/ or exp tanacetum parthenium/</LI>
<LI>exp harpagophytum/ or exp harpagophytum extract/ or exp harpagophytum procumbens extract/</LI>
<LI>or/49-73</LI>
<LI>36 and 48 and 74</LI>
<LI>limit 75 to yr="2013-Current"</LI>
<LI>limit 75 to em=201331-201436</LI>
<LI>76 or 77</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor: [Low Back Pain] this term only</P>
<P>#2 MeSH descriptor: [Back Pain] this term only</P>
<P>#3 backache</P>
<P>#4 lumbago</P>
<P>#5 #1 or #2 or #3 or #4</P>
<P>#6 MeSH descriptor: [Drugs, Chinese Herbal] explode all trees</P>
<P>#7 MeSH descriptor: [Plants, Medicinal] explode all trees</P>
<P>#8 herbal</P>
<P>#9 phytomedicine</P>
<P>#10 herb*</P>
<P>#11 weed</P>
<P>#12 MeSH descriptor: [Algae] explode all trees</P>
<P>#13 MeSH descriptor: [Fungi] explode all trees</P>
<P>#14 MeSH descriptor: [Medicine, Traditional] explode all trees</P>
<P>#15 MeSH descriptor: [Phytotherapy] this term only</P>
<P>#16 MeSH descriptor: [Pharmacognosy] explode all trees</P>
<P>#17 Oriental next traditional</P>
<P>#18 MeSH descriptor: [Medicine, Chinese Traditional] this term only</P>
<P>#19 Camphora next molmo</P>
<P>#20 MeSH descriptor: [Capsicum] this term only</P>
<P>#21 MeSH descriptor: [Salix] this term only</P>
<P>#22 Maleluca next alternifolia</P>
<P>#23 MeSH descriptor: [Angelica sinensis] this term only</P>
<P>#24 MeSH descriptor: [Aloe] this term only</P>
<P>#25 Thymus next officinalis</P>
<P>#26 Menthe next piperita</P>
<P>#27 MeSH descriptor: [Arnica] this term only</P>
<P>#28 Arnica next Montana</P>
<P>#29 Curcuma next longa</P>
<P>#30 MeSH descriptor: [Curcuma] this term only</P>
<P>#31 MeSH descriptor: [Tanacetum parthenium] this term only</P>
<P>#32 MeSH descriptor: [Harpagophytum] this term only</P>
<P>#33 Harpagophytum next procumbens</P>
<P>#34 Zingiber next officii</P>
<P>#35 MeSH descriptor: [Plant Preparations] this term only</P>
<P>#36 MeSH descriptor: [Plant Oils] explode all trees</P>
<P>#37 MeSH descriptor: [Plant Extracts] explode all trees</P>
<P>#38 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37</P>
<P>#39 #5 and #38</P>
<P>#40 #39 Publication Year from 2013 to 2014, in Trials</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL</HEADING>
<P>S75 S73 OR S74</P>
<P>S74 S73 and EM 20130806-20140911</P>
<P>S73 S49 and S71 Limiters - Published Date: 20130801-20140931</P>
<P>S72 S49 and S71</P>
<P>S71 S50 or S51 or S52 or S53 or S54 or S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or S70</P>
<P>S70 (MH "Devil's Claw")</P>
<P>S69 (MH "Feverfew")</P>
<P>S68 Curcuma longa</P>
<P>S67 (MH "Arnica")</P>
<P>S66 (MH "Aloe")</P>
<P>S65 (MH "Dong Quai")</P>
<P>S64 (MH "Willow Bark")</P>
<P>S63 ("Capsicum") or (MH "Cayenne Pepper")</P>
<P>S62 Camphora W1 molmol</P>
<P>S61 (MH "Medicine, Traditional")</P>
<P>S60 oriental W1 traditional</P>
<P>S59 Pharmacognosy</P>
<P>S58 ("Phytotherapy") or (MH "Medicine, Herbal")</P>
<P>S57 (MH "Medicine, Chinese Traditional")</P>
<P>S56 (MH "Fungi+")</P>
<P>S55 (MH "Algae+")</P>
<P>S54 "weed"</P>
<P>S53 herb*</P>
<P>S52 phytomedicine</P>
<P>S51 (MH "Plants, Medicinal+")</P>
<P>S50 (MH "Drugs, Chinese Herbal")</P>
<P>S49 S28 and S48</P>
<P>S48 S35 or S43 or S47</P>
<P>S47 S44 or S45 or S46</P>
<P>S46 "lumbago"</P>
<P>S45 (MH "Spondylolisthesis") OR (MH "Spondylolysis")</P>
<P>S44 (MH "Thoracic Vertebrae")</P>
<P>S43 S36 or S37 or S38 or S39 or S40 or S41 or S42</P>
<P>S42 lumbar N2 vertebra</P>
<P>S41 (MH "Lumbar Vertebrae")</P>
<P>S40 "coccydynia"</P>
<P>S39 "coccyx"</P>
<P>S38 "sciatica"</P>
<P>S37 (MH "Sciatica")</P>
<P>S36 (MH "Coccyx")</P>
<P>S35 S29 or S30 or S31 or S32 or S33 or S34</P>
<P>S34 lumbar N5 pain</P>
<P>S33 lumbar W1 pain</P>
<P>S32 "backache"</P>
<P>S31 (MH "Low Back Pain")</P>
<P>S30 (MH "Back Pain+")</P>
<P>S29 "dorsalgia"</P>
<P>S28 S26 NOT S27</P>
<P>S27 (MH "Animals")</P>
<P>S26 S7 or S12 or S19 or S25</P>
<P>S25 S20 or S21 or S22 or S23 or S24</P>
<P>S24 volunteer*</P>
<P>S23 prospectiv*</P>
<P>S22 control*</P>
<P>S21 followup stud*</P>
<P>S20 follow-up stud*</P>
<P>S19 S13 or S14 or S15 or S16 or S17 or S18</P>
<P>S18 (MH "Prospective Studies+")</P>
<P>S17 (MH "Evaluation Research+")</P>
<P>S16 (MH "Comparative Studies")</P>
<P>S15 latin square</P>
<P>S14 (MH "Study Design+")</P>
<P>S13 (MH "Random Sample")</P>
<P>S12 S8 or S9 or S10 or S11</P>
<P>S11 random*</P>
<P>S10 placebo*</P>
<P>S9 (MH "Placebos")</P>
<P>S8 (MH "Placebo Effect")</P>
<P>S7 S1 or S2 or S3 or S4 or S5 or S6</P>
<P>S6 triple-blind</P>
<P>S5 single-blind</P>
<P>S4 double-blind</P>
<P>S3 clinical W3 trial</P>
<P>S2 "randomi?ed controlled trial*"</P>
<P>S1 (MH "Clinical Trials+")</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ClinicalTrials.gov</HEADING>
<P>Condition: back pain</P>
<P>AND Intervention: herbal OR botanical</P>
<P>Received on or after 08/06/2013</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">WHO ICTRP</HEADING>
<P>Condition: back pain</P>
<P>AND Intervention: herbal OR botanical</P>
<P>Date of registration between 06/08/2013-(no date limit)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">PubMed</HEADING>
<P>((((herbal or botanical))) AND back pain) AND ((pubstatusaheadofprint OR publisher[sb] or pubmednotmedline[sb]))</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-12-18 11:51:32 -0500" MODIFIED_BY="Shireen Harbin" NO="2">
<TITLE MODIFIED="2014-12-18 08:59:23 -0500" MODIFIED_BY="Shireen Harbin">Previous search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-12-18 11:51:32 -0500" MODIFIED_BY="Shireen Harbin">
<SUBSECTION>
<HEADING LEVEL="3">August 2013</HEADING>
<P>
<B>Embase</B>
</P>
<P>The animal study filter was updated from 2010</P>
<OL>
<LI>Clinical Article/ </LI>
<LI>exp Clinical Study/ </LI>
<LI>Clinical Trial/ </LI>
<LI>Controlled Study/ </LI>
<LI>Randomized Controlled Trial/ </LI>
<LI>Major Clinical Study/ </LI>
<LI>Double Blind Procedure/ </LI>
<LI>Multicenter Study/ </LI>
<LI>Single Blind Procedure/ </LI>
<LI>Phase 3 Clinical Trial/ </LI>
<LI>Phase 4 Clinical Trial/ </LI>
<LI>crossover procedure/ </LI>
<LI>placebo/ </LI>
<LI>or/1-13 </LI>
<LI>allocat$.mp. </LI>
<LI>assign$.mp. </LI>
<LI>blind$.mp. </LI>
<LI>(clinic$ adj25 (study or trial)).mp. </LI>
<LI>compar$.mp. </LI>
<LI>control$.mp. </LI>
<LI>cross?over.mp. </LI>
<LI>factorial$.mp. </LI>
<LI>follow?up.mp. </LI>
<LI>placebo$.mp. </LI>
<LI>prospectiv$.mp. </LI>
<LI>random$.mp. </LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp. </LI>
<LI>trial.mp. </LI>
<LI>(versus or vs).mp. </LI>
<LI>or/15-29 </LI>
<LI>14 and 30 </LI>
<LI>exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/ </LI>
<LI>human/ or normal human/ or human cell/ </LI>
<LI>32 and 33 </LI>
<LI>32 not 34 </LI>
<LI>31 not 35 </LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">January 2011</HEADING>
<P>
<B>Medline</B>
</P>
<P>Back terms and herbal medicine terms were updated from 2009</P>
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>Randomized Controlled Trials/</LI>
<LI>Random Allocation/</LI>
<LI>Double-Blind Method/</LI>
<LI>Single-Blind Method/</LI>
<LI>or/1-6</LI>
<LI>Animals/ not Human/</LI>
<LI>7 not 8</LI>
<LI>clinical trial.pt.</LI>
<LI>exp Clinical Trials/</LI>
<LI>(clin$ adj25 trial$).tw.</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.</LI>
<LI>Placebos/</LI>
<LI>placebo$.tw.</LI>
<LI>random$.tw.</LI>
<LI>Research Design/</LI>
<LI>(latin adj square).tw.</LI>
<LI>or/10-18</LI>
<LI>19 not 18</LI>
<LI>20 not 9</LI>
<LI>Comparative Study/</LI>
<LI>exp Evaluation Studies/</LI>
<LI>Follow-Up Studies/</LI>
<LI>Prospective Studies/</LI>
<LI>(control$ or prospective$ or Volunteer$).tw.</LI>
<LI>Cross-Over Studies/</LI>
<LI>or/22-27</LI>
<LI>28 not 8</LI>
<LI>29 not (9 or 21)</LI>
<LI>9 or 21 or 30</LI>
<LI>dorsalgia.ti,ab.</LI>
<LI>exp Back Pain/</LI>
<LI>backache.ti,ab.</LI>
<LI>(lumbar adj pain).ti,ab.</LI>
<LI>coccyx.ti,ab.</LI>
<LI>coccydynia.ti,ab.</LI>
<LI>sciatica.ti,ab.</LI>
<LI>sciatic neuropathy/</LI>
<LI>spondylosis.ti,ab.</LI>
<LI>lumbago.ti,ab.</LI>
<LI>or/32-41</LI>
<LI>31 and 42</LI>
<LI>Drugs, Chinese Herbal/</LI>
<LI>herbal.mp.</LI>
<LI>Plants, Medicinal/</LI>
<LI>phytomedicine.mp.</LI>
<LI>herb$.mp.</LI>
<LI>weed.mp.</LI>
<LI>algae.mp.</LI>
<LI>cryptophyta/ or haptophyta/ or exp glaucophyta/ or exp rhodophyta/ or exp viridiplantae/ or exp chlorophyta/ or exp streptophyta/ or exp stramenopiles/</LI>
<LI>exp Fungi/</LI>
<LI>exp Medicine, Traditional/</LI>
<LI>exp Phytotherapy/</LI>
<LI>exp Pharmacognosy/</LI>
<LI>(oriental adj traditional).mp.</LI>
<LI>(Camphora adj molmol).mp.</LI>
<LI>Capsicum/</LI>
<LI>exp Salicaceae/</LI>
<LI>(Maleluca adj alternifolia).mp.</LI>
<LI>Angelica sinensis/</LI>
<LI>Aloe/</LI>
<LI>(Thymus adj officinalis).mp.</LI>
<LI>Menthe piperita.mp.</LI>
<LI>Arnica Montana.mp. or Arnica/</LI>
<LI>Curcuma longa.mp. or Curcuma/</LI>
<LI>Tanacetum parthenium.mp. or Tanacetum parthenium/</LI>
<LI>feverfew.mp.</LI>
<LI>Harpagophytum procumbens.mp. or exp Harpagophytum/</LI>
<LI>Zingiber officii.mp.</LI>
<LI>plant preparations/ or plant extracts/ or plant oils/</LI>
<LI>or/44-71</LI>
<LI>43 and 72</LI>
<LI>limit 73 to yr="2003 - 2011"</LI>
</OL>
<P>
<B>CINAHL</B>
</P>
<P>The strategy was updated from 2009</P>
<P>S73 S49 and S71 Limiters - Published Date from: 20030101-20111231</P>
<P>S72 S49 and S71</P>
<P>S71 S50 or S51 or S52 or S53 or S54 or S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or S68 or S69 or S70</P>
<P>S70 (MH "Devil's Claw")</P>
<P>S69 (MH "Feverfew")</P>
<P>S68 Curcuma longa</P>
<P>S67 (MH "Arnica")</P>
<P>S66 (MH "Aloe")</P>
<P>S65 (MH "Dong Quai")</P>
<P>S64 (MH "Willow Bark")</P>
<P>S63 ("Capsicum") or (MH "Cayenne Pepper")</P>
<P>S62 Camphora W1 molmol</P>
<P>S61 (MH "Medicine, Traditional")</P>
<P>S60 oriental W1 traditional</P>
<P>S59 Pharmacognosy</P>
<P>S58 ("Phytotherapy") or (MH "Medicine, Herbal")</P>
<P>S57 (MH "Medicine, Chinese Traditional")</P>
<P>S56 (MH "Fungi+")</P>
<P>S55 (MH "Algae+")</P>
<P>S54 "weed"</P>
<P>S53 herb*</P>
<P>S52 phytomedicine</P>
<P>S51 (MH "Plants, Medicinal+")</P>
<P>S50 (MH "Drugs, Chinese Herbal")</P>
<P>S49 S28 and S48</P>
<P>S48 S35 or S43 or S47</P>
<P>S47 S44 or S45 or S46</P>
<P>S46 "lumbago"</P>
<P>S45 (MH "Spondylolisthesis") OR (MH "Spondylolysis")</P>
<P>S44 (MH "Thoracic Vertebrae")</P>
<P>S43 S36 or S37 or S38 or S39 or S40 or S41 or S42</P>
<P>S42 lumbar N2 vertebra</P>
<P>S41 (MH "Lumbar Vertebrae")</P>
<P>S40 "coccydynia"</P>
<P>S39 "coccyx"</P>
<P>S38 "sciatica"</P>
<P>S37 (MH "Sciatica")</P>
<P>S36 (MH "Coccyx")</P>
<P>S35 S29 or S30 or S31 or S32 or S33 or S34</P>
<P>S34 lumbar N5 pain</P>
<P>S33 lumbar W1 pain</P>
<P>S32 "backache"</P>
<P>S31 (MH "Low Back Pain")</P>
<P>S30 (MH "Back Pain+")</P>
<P>S29 "dorsalgia"</P>
<P>S28 S26 NOT S27</P>
<P>S27 (MH "Animals")</P>
<P>S26 S7 or S12 or S19 or S25</P>
<P>S25 S20 or S21 or S22 or S23 or S24</P>
<P>S24 volunteer*</P>
<P>S23 prospectiv*</P>
<P>S22 control*</P>
<P>S21 followup stud*</P>
<P>S20 follow-up stud*</P>
<P>S19 S13 or S14 or S15 or S16 or S17 or S18</P>
<P>S18 (MH "Prospective Studies+")</P>
<P>S17 (MH "Evaluation Research+")</P>
<P>S16 (MH "Comparative Studies")</P>
<P>S15 latin square</P>
<P>S14 (MH "Study Design+")</P>
<P>S13 (MH "Random Sample")</P>
<P>S12 S8 or S9 or S10 or S11</P>
<P>S11 random*</P>
<P>S10 placebo*</P>
<P>S9 (MH "Placebos")</P>
<P>S8 (MH "Placebo Effect")</P>
<P>S7 S1 or S2 or S3 or S4 or S5 or S6</P>
<P>S6 triple-blind</P>
<P>S5 single-blind</P>
<P>S4 double-blind</P>
<P>S3 clinical W3 trial</P>
<P>S2 "randomi?ed controlled trial*"</P>
<P>S1 (MH "Clinical Trials+")</P>
<P>
<B>CENTRAL</B>
</P>
<P>New intervention terms were added from 2009</P>
<P>#1 MeSH descriptor Low Back Pain, this term only</P>
<P>#2 MeSH descriptor Back Pain, this term only</P>
<P>#3 backache</P>
<P>#4 lumbago</P>
<P>#5 (#1 OR #2 OR #3 OR #4)</P>
<P>#6 MeSH descriptor Drugs, Chinese Herbal explode all trees</P>
<P>#7 MeSH descriptor Plants, Medicinal explode all trees</P>
<P>#8 herbal</P>
<P>#9 phytomedicine</P>
<P>#10 herb*</P>
<P>#11 weed</P>
<P>#12 MeSH descriptor Algae explode all trees</P>
<P>#13 MeSH descriptor Fungi explode all trees</P>
<P>#14 MeSH descriptor Medicine, Traditional explode all trees</P>
<P>#15 MeSH descriptor Phytotherapy, this term only</P>
<P>#16 MeSH descriptor Pharmacognosy explode all trees</P>
<P>#17 Oriental NEXT traditional</P>
<P>#18 MeSH descriptor Medicine, Chinese Traditional, this term only</P>
<P>#19 Camphora NEXT molmo</P>
<P>#20 MeSH descriptor Capsicum, this term only</P>
<P>#21 MeSH descriptor Salix, this term only</P>
<P>#22 Maleluca NEXT alternifolia</P>
<P>#23 MeSH descriptor Angelica sinensis, this term only</P>
<P>#24 MeSH descriptor Aloe, this term only</P>
<P>#25 Thymus NEXT officinalis</P>
<P>#26 Menthe NEXT piperita</P>
<P>#27 MeSH descriptor Arnica, this term only</P>
<P>#28 Arnica NEXT Montana</P>
<P>#29 Curcuma NEXT longa</P>
<P>#30 MeSH descriptor Curcuma, this term only</P>
<P>#31 MeSH descriptor Tanacetum parthenium, this term only</P>
<P>#32 MeSH descriptor Harpagophytum, this term only</P>
<P>#33 Harpagophytum NEXT procumbens</P>
<P>#34 Zingiber NEXT officii</P>
<P>#35 MeSH descriptor Plant Preparations, this term only</P>
<P>#36 MeSH descriptor Plant Oils explode all trees</P>
<P>#37 MeSH descriptor Plant Extracts explode all trees</P>
<P>#38 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37)</P>
<P>#39 (#5 AND #38), from 2003 to 2011</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">April 2010</HEADING>
<P>
<B>EMBASE</B>
</P>
<P>The strategy was updated from 2009</P>
<OL>
<LI>Clinical Article/</LI>
<LI>exp Clinical Study/</LI>
<LI>Clinical Trial/</LI>
<LI>Controlled Study/</LI>
<LI>Randomized Controlled Trial/</LI>
<LI>Major Clinical Study/</LI>
<LI>Double Blind Procedure/</LI>
<LI>Multicenter Study/</LI>
<LI>Single Blind Procedure/</LI>
<LI>Phase 3 Clinical Trial/</LI>
<LI>Phase 4 Clinical Trial/</LI>
<LI>crossover procedure/</LI>
<LI>placebo/</LI>
<LI>or/1-13</LI>
<LI>allocat$.mp.</LI>
<LI>assign$.mp.</LI>
<LI>blind$.mp.</LI>
<LI>(clinic$ adj25 (study or trial)).mp.</LI>
<LI>compar$.mp.</LI>
<LI>control$.mp.</LI>
<LI>cross?over.mp.</LI>
<LI>factorial$.mp.</LI>
<LI>follow?up.mp.</LI>
<LI>placebo$.mp.</LI>
<LI>prospectiv$.mp.</LI>
<LI>random$.mp.</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.</LI>
<LI>trial.mp.</LI>
<LI>(versus or vs).mp.</LI>
<LI>or/15-29</LI>
<LI>14 and 30</LI>
<LI>human/</LI>
<LI>Nonhuman/</LI>
<LI>exp ANIMAL/</LI>
<LI>Animal Experiment/</LI>
<LI>33 or 34 or 35</LI>
<LI>32 not 36</LI>
<LI>31 not 36</LI>
<LI>37 and 38</LI>
<LI>38 or 39</LI>
<LI>dorsalgia.mp.</LI>
<LI>back pain.mp.</LI>
<LI>exp BACKACHE/</LI>
<LI>(lumbar adj pain).mp.</LI>
<LI>coccyx.mp.</LI>
<LI>coccydynia.mp.</LI>
<LI>sciatica.mp.</LI>
<LI>exp ISCHIALGIA/</LI>
<LI>spondylosis.mp.</LI>
<LI>lumbago.mp.</LI>
<LI>exp Low back pain/</LI>
<LI>or/41-51</LI>
<LI>exp herbaceous agent/</LI>
<LI>herbal.mp.</LI>
<LI>exp medicinal plant/</LI>
<LI>exp phytotherapy/</LI>
<LI>exp herbal medicine/</LI>
<LI>phytomedicine.mp.</LI>
<LI>exp plant extract/</LI>
<LI>herb*.mp.</LI>
<LI>weed.mp.</LI>
<LI>exp alga/</LI>
<LI>exp fungus/</LI>
<LI>exp traditional medicine/</LI>
<LI>exp pharmacognosy/</LI>
<LI>(oriental adj traditional).mp.</LI>
<LI>exp Chinese medicine/</LI>
<LI>exp pepper/</LI>
<LI>capsicum.mp.</LI>
<LI>exp willow/</LI>
<LI>salix.mp.</LI>
<LI>exp Angelica sinensis/</LI>
<LI>exp Aloe/</LI>
<LI>exp Arnica montana/</LI>
<LI>exp Curcuma longa/</LI>
<LI>tanacetum/ or exp tanacetum parthenium/</LI>
<LI>exp harpagophytum/ or exp harpagophytum extract/ or exp harpagophytum procumbens extract/</LI>
<LI>or/53-77</LI>
<LI>40 and 52 and 78</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">October-November 2009 </HEADING>
<P>
<B>Medline</B>
</P>
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>Randomized Controlled Trials/</LI>
<LI>Random Allocation/</LI>
<LI>Double-Blind Method/</LI>
<LI>Single-Blind Method/</LI>
<LI>or/1-6</LI>
<LI>Animal/ not Human/</LI>
<LI>7 not 8</LI>
<LI>clinical trial.pt.</LI>
<LI>exp Clinical Trial/</LI>
<LI>(clinic$ adj trial$).tw.</LI>
<LI>((single$ or double$ or treble$ or triple$) adj (mask$ or blind$)).tw.</LI>
<LI>Placebos/</LI>
<LI>placebo$.tw.</LI>
<LI>random$.tw.</LI>
<LI>Research Design/</LI>
<LI>(Latin adj square).tw.</LI>
<LI>or/10-18</LI>
<LI>19 not 8</LI>
<LI>20 not 9</LI>
<LI>Comparative Study/</LI>
<LI>exp Evaluation Studies/</LI>
<LI>Follow-Up Studies/</LI>
<LI>Prospective Studies/</LI>
<LI>(control$ or prospective$ or volunteer$).tw.</LI>
<LI>Cross-Over Studies/</LI>
<LI>or/22-27</LI>
<LI>28 not 8</LI>
<LI>29 not (9 or 21)</LI>
<LI>9 or 21 or 30</LI>
<LI>low back pain/</LI>
<LI>low back pain.tw.</LI>
<LI>backache.mp.</LI>
<LI>lumbago.mp.</LI>
<LI>or/32-35</LI>
<LI>exp Drugs, Chinese Herbal/</LI>
<LI>herbal.tw.</LI>
<LI>exp Plants, Medicinal/</LI>
<LI>phytomedicine.tw.</LI>
<LI>herb$.tw.</LI>
<LI>weed.tw.</LI>
<LI>exp Algae/</LI>
<LI>exp Fungi/</LI>
<LI>Medicine, Traditional/</LI>
<LI>exp Phytotherapy/</LI>
<LI>exp Pharmacognosy/</LI>
<LI>(oriental adj traditional).tw.</LI>
<LI>exp Medicine, Chinese Traditional/</LI>
<LI>(Camphora adj molmol).tw.</LI>
<LI>Capsicum/</LI>
<LI>Salix/</LI>
<LI>(Maleluca adj alternifolia).tw.</LI>
<LI>exp Angelica sinensis/</LI>
<LI>Aloe/</LI>
<LI>(Thymus adj officinalis).tw.</LI>
<LI>Menthe piperita.tw.</LI>
<LI>Arnica Montana.mp. or exp Arnica/</LI>
<LI>Curcuma longa.mp. or exp Curcuma/</LI>
<LI>exp Tanacetum parthenium/</LI>
<LI>Harpagophytum procumbens.mp. or exp Harpagophytum/</LI>
<LI>Zingiber officii.tw.</LI>
<LI>or/37-62</LI>
<LI>31 and 36 and 63</LI>
<LI>limit 64 to yr="2005 -Current"</LI>
</OL>
<P>
<B>Embase</B>
</P>
<OL>
<LI>Randomized Controlled Trials/</LI>
<LI>Random Allocation/</LI>
<LI>Double-Blind Method/</LI>
<LI>Single-Blind Method/</LI>
<LI>4 or 1 or 3 or 2</LI>
<LI>Animal/ not Human/</LI>
<LI>5 not 6</LI>
<LI>exp clinical trial/</LI>
<LI>(clinic$ adj trial$).tw.</LI>
<LI>((single$ or double$ or treble$ or triple$) adj (mask$ or blind$)).tw.</LI>
<LI>Placebos/</LI>
<LI>placebo$.tw.</LI>
<LI>random$.tw.</LI>
<LI>Research Design/</LI>
<LI>(Latin adj square).tw.</LI>
<LI>or/8-15</LI>
<LI>16 not 6</LI>
<LI>17 not 7</LI>
<LI>Comparative Study/</LI>
<LI>exp Evaluation Studies/</LI>
<LI>Follow-Up Studies/</LI>
<LI>Prospective Studies/</LI>
<LI>(control$ or prospective$ or volunteer$).tw.</LI>
<LI>Cross-Over Studies/</LI>
<LI>or/19-24</LI>
<LI>25 not 6</LI>
<LI>26 not (7 or 18)</LI>
<LI>7 or 18 or 27</LI>
<LI>low back pain/</LI>
<LI>low back pain.tw.</LI>
<LI>backache.mp. or exp backache/</LI>
<LI>lumbago.mp.</LI>
<LI>/29-32</LI>
<LI>exp Drugs, Chinese Herbal/</LI>
<LI>herbal.tw.</LI>
<LI>exp Plants, Medicinal/</LI>
<LI>phytomedicine.tw.</LI>
<LI>herb$.tw.</LI>
<LI>weed.tw.</LI>
<LI>exp Algae/</LI>
<LI>exp Fungi/</LI>
<LI>Medicine, Traditional/</LI>
<LI>exp Phytotherapy/</LI>
<LI>exp Pharmacognosy/</LI>
<LI>(oriental adj traditional).tw.</LI>
<LI>exp Medicine, Chinese Traditional/</LI>
<LI>(Camphora adj molmol).tw.</LI>
<LI>Capsicum/</LI>
<LI>Salix/</LI>
<LI>(Maleluca adj alternifolia).tw.</LI>
<LI>exp Angelica sinensis/</LI>
<LI>Aloe/</LI>
<LI>(Thymus adj officinalis).tw.</LI>
<LI>Menthe piperita.tw.</LI>
<LI>Arnica Montana.mp. or exp Arnica/</LI>
<LI>Curcuma longa.mp. or exp Curcuma/</LI>
<LI>exp Tanacetum parthenium/</LI>
<LI>Harpagophytum procumbens.mp. or exp Harpagophytum/</LI>
<LI>Zingiber officii.tw.</LI>
<LI>or/34-59</LI>
<LI>28 and 33 and 60</LI>
<LI>limit 61 to yr="2005 -Current"</LI>
</OL>
<P>
<B>CENTRAL</B>
</P>
<P>#1 MeSH descriptor Low Back Pain, this term only</P>
<P>#2 MeSH descriptor Back Pain, this term only</P>
<P>#3 backache</P>
<P>#4 lumbago</P>
<P>#5 (#1 OR #2 OR #3 OR #4)</P>
<P>#6 MeSH descriptor Drugs, Chinese Herbal explode all trees</P>
<P>#7 MeSH descriptor Plants, Medicinal explode all trees</P>
<P>#8 herbal</P>
<P>#9 phytomedicine</P>
<P>#10 herb*</P>
<P>#11 weed</P>
<P>#12 MeSH descriptor Algae explode all trees</P>
<P>#13 MeSH descriptor Fungi explode all trees</P>
<P>#14 MeSH descriptor Medicine, Traditional explode all trees</P>
<P>#15 MeSH descriptor Phytotherapy, this term only</P>
<P>#16 MeSH descriptor Pharmacognosy explode all trees</P>
<P>#17 Oriental NEXT traditional</P>
<P>#18 MeSH descriptor Medicine, Chinese Traditional, this term only</P>
<P>#19 Camphora NEXT molmo</P>
<P>#20 MeSH descriptor Capsicum, this term only</P>
<P>#21 MeSH descriptor Salix, this term only</P>
<P>#22 Maleluca NEXT alternifolia</P>
<P>#23 MeSH descriptor Angelica sinensis, this term only</P>
<P>#24 MeSH descriptor Aloe, this term only</P>
<P>#25 Thymus NEXT officinalis</P>
<P>#26 Menthe NEXT piperita</P>
<P>#27 MeSH descriptor Arnica, this term only</P>
<P>#28 Arnica NEXT Montana</P>
<P>#29 Curcuma NEXT longa</P>
<P>#30 MeSH descriptor Curcuma, this term only</P>
<P>#31 MeSH descriptor Tanacetum parthenium, this term only</P>
<P>#32 MeSH descriptor Harpagophytum, this term only</P>
<P>#33 Harpagophytum NEXT procumbens</P>
<P>#34 Zingiber NEXT officii</P>
<P>#35 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34)</P>
<P>#36 (#5 AND #35)</P>
<P>#37 (#36), from 2005 to 2009 (Searched with limiter Clinical Trials)</P>
<P>
<B>CINAHL</B>
</P>
<P>S55 S54 and S28 and S32</P>
<P>S54 S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51 or S52 or S53</P>
<P>S53 (MH "Devil's Claw")</P>
<P>S52 (MH "Feverfew")</P>
<P>S51 Curcuma longa</P>
<P>S50 (MH "Arnica")</P>
<P>S49 (MH "Aloe")</P>
<P>S48 (MH "Dong Quai")</P>
<P>S47 (MH "Willow Bark")</P>
<P>S46 ("Capsicum") or (MH "Cayenne Pepper")</P>
<P>S45 Camphora W1 molmol</P>
<P>S44 (MH "Medicine, Traditional")</P>
<P>S43 oriental W1 traditional</P>
<P>S42 Pharmacognosy</P>
<P>S41 ("Phytotherapy") or (MH "Medicine, Herbal")</P>
<P>S40 (MH "Medicine, Chinese Traditional")</P>
<P>S39 (MH "Fungi+")</P>
<P>S38 (MH "Algae+")</P>
<P>S37 "weed"</P>
<P>S36 herb*</P>
<P>S35 phytomedicine</P>
<P>S34 (MH "Plants, Medicinal+")</P>
<P>S33 (MH "Drugs, Chinese Herbal")</P>
<P>S32 S29 or S30 or S31</P>
<P>S31 "lumbago"</P>
<P>S30 "backache"</P>
<P>S29 ("low back pain") or (MH "Low Back Pain")</P>
<P>S28 S8 or S18 or S27</P>
<P>S27 S26 not (S18 or S8)</P>
<P>S26 S25 not S7</P>
<P>S25 S19 or S20 or S21 or S22 or S23 or S24</P>
<P>S24 (MH "Crossover Design")</P>
<P>S23 "Follow-up Studies"</P>
<P>S22 control* or prospective* or volunteer*</P>
<P>S21 (MH "Prospective Studies")</P>
<P>S20 (MH "Evaluation Research+")</P>
<P>S19 (MH "Comparative Studies")</P>
<P>S18 S17 not S8</P>
<P>S17 S16 not S7</P>
<P>S16 S9 or S10 or S11 or S12 or S13 or S14 or S15</P>
<P>S15 Latin W1 Square</P>
<P>S14 (MH "Study Design")</P>
<P>S13 random*</P>
<P>S12 placebo*</P>
<P>S11 (MH "Placebos")</P>
<P>S10 clinic* W2 trial*</P>
<P>S9 "clinical trial"</P>
<P>S8 S6 not S7</P>
<P>S7 (MH "Animals") not ("Human")</P>
<P>S6 S1 or S2 or S3 or S4 or S5</P>
<P>S5 "Single-Blind Method"</P>
<P>S4 "randomized controlled trial"</P>
<P>S3 "Double-Blind Method"</P>
<P>S2 (MH "Random Assignment")</P>
<P>S1 (MH "Clinical Trials+")</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-09-02 18:52:14 -0400" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-11-29 13:33:07 -0500" MODIFIED_BY="[Empty name]">Criteria for assessing risk of bias for internal validity</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-02 18:52:14 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Random sequence generation (selection bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence</HEADING>
<P>There is a low risk of selection bias if the investigators describe a random component in the sequence generation process such as: referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots, minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random).</P>
<P>There is a high risk of selection bia<I>s</I> if the investigators describe a non-random component in the sequence generation process, such as: sequence generated by odd or even date of birth, date (or day) of admission, hospital or clinic record number; or allocation by judgement of the clinician, preference of the participant, results of a laboratory test or a series of tests, or availability of the intervention.</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment (selection bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</HEADING>
<P>There is a low risk of selection bias if the participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomization); sequentially numbered drug containers of identical appearance; or sequentially numbered, opaque, sealed envelopes.</P>
<P>There is a high risk of bias if participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; or other explicitly unconcealed procedures.</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding of participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Performance bias due to knowledge of the allocated interventions by participants during the study</HEADING>
<P>There is a low risk of performance bias if blinding of participants was ensured and it was unlikely that the blinding could have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding.</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding of personnel or care providers (performance bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Performance bias due to knowledge of the allocated interventions by personnel or care providers during the study</HEADING>
<P>There is a low risk of performance bias if blinding of personnel was ensured and it was unlikely that the blinding could have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding.</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding of outcome assessors (detection bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Detection bias due to knowledge of the allocated interventions by outcome assessors</HEADING>
<P>There is low risk of detection bias if the blinding of the outcome assessment was ensured and it was unlikely that the blinding could have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding, or:</P>
<UL>
<LI>for patient-reported outcomes in which the patient was the outcome assessor (e.g. pain, disability): there is a low risk of bias for outcome assessors if there is a low risk of bias for participant blinding (<LINK REF="REF-Boutron-2005" TYPE="REFERENCE">Boutron 2005</LINK>);</LI>
<LI>for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between patients and care providers (e.g. co-interventions, length of hospitalisation, treatment failure), in which the care provider is the outcome assessor: there is a low risk of bias for outcome assessors if there is a low risk of bias for care providers (<LINK REF="REF-Boutron-2005" TYPE="REFERENCE">Boutron 2005</LINK>);</LI>
<LI>for outcome criteria that are assessed from data from medical forms: there is a low risk of bias if the treatment or adverse effects of the treatment could not be noticed in the extracted data (<LINK REF="REF-Boutron-2005" TYPE="REFERENCE">Boutron 2005</LINK>).</LI>
</UL>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incomplete outcome data (attrition bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Attrition bias due to amount, nature or handling of incomplete outcome data</HEADING>
<P>There is a low risk of attrition bias if there were no missing outcome data; reasons for missing outcome data were unlikely to be related to the true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data were balanced in numbers, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, the plausible effect size (difference in means or standardised difference in means) among missing outcomes was not enough to have a clinically relevant impact on observed effect size, or missing data were imputed using appropriate methods (if drop-outs are very large, imputation using even "acceptable" methods may still suggest a high risk of bias) (<LINK REF="REF-van-Tulder-2003" TYPE="REFERENCE">van Tulder 2003</LINK>). The percentage of withdrawals and drop-outs should not exceed 20% for short-term follow-up and 30% for long-term follow-up and should not lead to substantial bias (these percentages are commonly used but arbitrary, not supported by literature) (<LINK REF="REF-van-Tulder-2003" TYPE="REFERENCE">van Tulder 2003</LINK>).</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selective reporting (reporting bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Reporting bias due to selective outcome reporting</HEADING>
<P>There is low risk of reporting bias if the study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way, or if the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
<P>There is a high risk of reporting bias if not all of the study's pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Group similarity at baseline (selection bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bias due to dissimilarity at baseline for the most important prognostic indicators.</HEADING>
<P>There is low risk of bia<I>s</I> if groups are similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factors (examples in the field of back and neck pain are duration and severity of complaints, vocational status, percentage of patients with neurological symptoms) (<LINK REF="REF-van-Tulder-2003" TYPE="REFERENCE">van Tulder 2003</LINK>).</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Co-interventions (performance bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bias because co-interventions were different across groups</HEADING>
<P>There is low risk of bias if there were no co-interventions or they were similar between the index and control groups (<LINK REF="REF-van-Tulder-2003" TYPE="REFERENCE">van Tulder 2003</LINK>).</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Compliance (performance bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bias due to inappropriate compliance with interventions across groups</HEADING>
<P>There is low risk of bias if compliance with the interventions was acceptable, based on the reported intensity or dosage, duration, number and frequency for both the index and control intervention(s). For single-session interventions (e.g. surgery), this item is irrelevant (<LINK REF="REF-van-Tulder-2003" TYPE="REFERENCE">van Tulder 2003</LINK>).</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat-analysis</HEADING>
<P>There is low risk of bias if all randomized patients were reported or analysed in the group to which they were allocated by randomization.</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Timing of outcome assessments (detection bias)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bias because important outcomes were not measured at the same time across groups</HEADING>
<P>There is low risk of bias if all important outcome assessments for all intervention groups were measured at the same time (<LINK REF="REF-van-Tulder-2003" TYPE="REFERENCE">van Tulder 2003</LINK>).</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other bias</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bias due to problems not covered elsewhere in the table</HEADING>
<P>There is a low risk of bias if the study appears to be free of other sources of bias not addressed elsewhere (e.g. study funding).</P>
<P>Unclear' reflected the fact that there was insufficient information to determine whether this criterion was fulfilled or not.</P>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>